[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 181
1. Nakamura M, Shimada K, Ishida E, Higuchi T, Nakase H, Sakaki T, Konishi N: Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol; 2007 Apr;9(2):113-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of pediatric astrocytic tumors.
  • Astrocytomas are the most common pediatric brain tumors, accounting for 7%-8% of all childhood cancers.
  • Relatively few studies have been performed on their molecular properties; therefore, classification of pediatric astrocytic tumors into genetic subtypes similar to that of adult tumors remains to be defined.
  • Here, we report an extensive characterization of 44 pediatric astrocytomas--16 diffuse astrocytomas (WHO grade II), 10 anaplastic astrocytomas (WHO grade III), and 18 glioblastomas (WHO grade IV)--in terms of genetic alterations frequently observed in adult astrocytomas.
  • Loss of heterozygosity (LOH) on 1p/19q and 10p/10q was less common in pediatric astrocytic tumors than in those seen in adults, but the frequency of LOH on 22q was comparable, occurring in 44% of diffuse astrocytomas, 40% of anaplastic astrocytomas, and 61% of glioblastomas.
  • Interestingly, a higher frequency of p53 mutations and LOH on 19q and 22q in tumors from children six or more years of age at diagnosis was found, compared with those from younger children.
  • Our results suggest some differences in children compared to adults in the genetic pathways leading to the formation of de novo astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Acta Neuropathol. 2005 Oct;110(4):402-10 [16155764.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] Brain Pathol. 2000 Apr;10(2):249-59 [10764044.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43 [10850866.001]
  • [Cites] Lab Invest. 2001 Jan;81(1):77-82 [11204276.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):117-22 [12241104.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):737-41 [12591717.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 1990 May 15;50(10):2987-90 [2334901.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3229-36 [8490859.001]
  • [Cites] Brain Pathol. 1993 Jan;3(1):19-26 [8269081.001]
  • [Cites] Oncogene. 1994 Mar;9(3):949-54 [8108140.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):213-9; discussion 219-20 [8177380.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):967-72; discussion 972-3 [8084407.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):258-64 [8869052.001]
  • [Cites] Cytogenet Cell Genet. 1996;72(2-3):100-12 [8978759.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):755-64 [9161727.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):782-9 [9210874.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):9-15 [9591629.001]
  • [Cites] Acta Neuropathol. 1998 Jun;95(6):559-64 [9650746.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jul;57(7):684-9 [9690672.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):165-75 [15592495.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4085-90 [10632344.001]
  • (PMID = 17327574.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC1871665
  •  go-up   go-down


2. Ambroise MM, Khosla C, Ghosh M, Mallikarjuna VS, Annapurneswari S: The role of immunohistochemistry in predicting behavior of astrocytic tumors. Asian Pac J Cancer Prev; 2010;11(4):1079-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in predicting behavior of astrocytic tumors.
  • The purpose of this study was to analyze the significance of p53, bcl-2 and EGFR expression in the grading and biological behavior of astrocytic tumors, especially in the Indian population.
  • Our results showed that p53 alterations is an early event in astrocytic gliomagenesis, but is not significant in the evolution of pilocytic astrocytomas.
  • EGFR protein expression correlated with the severity of tumor grade.
  • [MeSH-major] Astrocytoma / chemistry. Glioblastoma / chemistry. Nervous System Neoplasms / chemistry. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptor, Epidermal Growth Factor / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Age Factors. Female. Genes, bcl-2. Genes, erbB-1. Genes, p53. Humans. Immunohistochemistry. India. Male. Middle Aged. Prognosis. Sex Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133628.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


3. Shen CF, Yuan XR, Qin ZQ: [Clinical significance of the expression of the RCAS1 mRNA and protein in astrocytic tumors]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Oct;32(5):836-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of the expression of the RCAS1 mRNA and protein in astrocytic tumors].
  • OBJECTIVE: To determine the mRNA and protein expressions of RCAS1 in human astrocytic tumors, and to explore the relation between their expression and the genesis and development of tumor.
  • METHODS: The RCAS1 mRNA expression in human astrocytic tumors was evaluated by RT-PCR, and the RCAS1 protein expression was studied by immunohistochemical staining.
  • RCAS1 protein expression was positively correlated with the tumor grade (r=0.573,P<0.001).
  • The RCAS1 protein was not detected in normal brain tissues by immunohistochemical staining.
  • CONCLUSION: The RCAS1 expression is related to the histological grade of astrocytic tumor.
  • In astrocytic tumors, the RCAS1 expression is regulated transcriptionally and posttranscriptionally.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. RNA, Messenger / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18007080.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / EBAG9 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


Advertisement
4. Liebrich M, Guo LH, Schluesener HJ, Schwab JM, Dietz K, Will BE, Meyermann R: Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Arch Immunol Ther Exp (Warsz); 2007 Jan-Feb;55(1):41-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors.
  • MATERIALS AND METHODS: Expression of IL-16 was analyzed by immunohistochemistry in human astrocytic brain tumors and the rat C6 glioblastoma tumor model.
  • IL-16 was detected in both human astrocytic brain tumors and rat C6 glioma.
  • RESULTS: Compared with human control brains, a significant increase in the percentages of parenchymal IL-16+ macrophages/microglia was observed already in grade II astrocytomas, indicating that IL-16+ immunostaining could be a descriptor of a macrophage/microglia subset in astrocytic brain tumors.
  • This increase in IL-16 immunoreactivity correlated with WHO grades of human astrocytic brain tumors.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-16 / biosynthesis. Macrophages / immunology. Microglia / immunology
  • [MeSH-minor] Adult. Aged. Animals. Cell Line, Tumor. Female. Humans. Inflammation Mediators / metabolism. Male. Middle Aged. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 May 1;164(9):4429-32 [10779741.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):752-3 [15944689.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Int J Dev Neurosci. 2001 Feb;19(1):93-100 [11226758.001]
  • [Cites] Acta Neuropathol. 2001 Mar;101(3):249-55 [11307625.001]
  • [Cites] Microsc Res Tech. 2001 Jul 15;54(2):106-13 [11455617.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):141-7 [11859968.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):947-56 [12213723.001]
  • [Cites] Glia. 2002 Nov;40(2):252-9 [12379912.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4410-9 [12805281.001]
  • [Cites] J Neuroimmunol. 2004 Jan;146(1-2):39-45 [14698845.001]
  • [Cites] Glia. 2004 Jan 15;45(2):208-12 [14730714.001]
  • [Cites] J Leukoc Biol. 2004 Mar;75(3):388-97 [14612429.001]
  • [Cites] J Immunol. 1982 Jun;128(6):2563-8 [7042840.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):149-61 [8153661.001]
  • [Cites] Nature. 1996 May 2;381(6577):29-30 [8609983.001]
  • [Cites] J Neurosci Res. 1996 Jun 15;44(6):606-11 [8794952.001]
  • [Cites] Glia. 1997 Aug;20(4):365-72 [9262239.001]
  • [Cites] Nature. 1998 Apr 30;392(6679):936-41 [9582076.001]
  • [Cites] Int Rev Immunol. 1998;16(5-6):523-40 [9646175.001]
  • [Cites] Prog Neurobiol. 1999 Jun;58(3):233-47 [10341362.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Acta Neuropathol. 2000 Sep;100(3):313-22 [10965802.001]
  • (PMID = 17221335.001).
  • [ISSN] 0004-069X
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Interleukin-16
  • [Other-IDs] NLM/ PMC3234149
  •  go-up   go-down


5. Shrestha P, Saito T, Hama S, Arifin MT, Kajiwara Y, Yamasaki F, Hidaka T, Sugiyama K, Kurisu K: Geminin: a good prognostic factor in high-grade astrocytic brain tumors. Cancer; 2007 Mar 1;109(5):949-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geminin: a good prognostic factor in high-grade astrocytic brain tumors.
  • For this study, the authors investigated geminin expression in high-grade astrocytic tumors, including anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), with a view to predicting clinical outcomes on this basis in patients with these malignant brain tumors.
  • METHODS: Immunohistochemistry was used to detect geminin expression in 51 patients with high-grade astrocytic tumors (19 AA and 32 GBM).
  • The relation of geminin expression to clinical outcome in these malignant brain tumors was analyzed by using the Kaplan-Meier method and a Cox proportional hazards regression model.
  • CONCLUSIONS: Although it is an inhibitor of DNA proliferation and, thus, is a cell cycle inhibitor, geminin expression was found in all malignant astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cell Cycle Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Female. Geminin. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17262828.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin
  •  go-up   go-down


6. Isolan GR, Ribas Filho JM, Isolan PM, Giovanini A, Malafaia O, Dini LI, Kummer A Jr, Negrão AW: [Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins]. Arq Neuropsiquiatr; 2005 Dec;63(4):997-1004
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins].
  • The astrocytic neoplasms respond by 60% of the central nervous system tumors, being the study of the molecular biology an important step for the understanding of the genesis and biological behavior of these diseases.
  • The Ki-67 proteins, which are markers of the cellular proliferation, and p53, which is the product of the tumor suppressor gene TP53, are both important tumoral markers.
  • This study intends to identify and quantify the Ki-67 and p53 proteins in astrocytic tumors of different grades of malignancy, as well as to analyze their relations with age and gender.
  • Ki-67 and p53 proteins in 47 patients with surgically resected astrocytic neoplasms were studied through immunohistochemistry.
  • The hypotheses of a greater presence of Ki-67 and p53 in astrocytic neoplasms with a higher degree of malignancy, except for the correlation between grade III and p53, is corroborated by the results of this study.
  • [MeSH-major] Astrocytoma / chemistry. Central Nervous System Neoplasms / chemistry. Ki-67 Antigen / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400419.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


7. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastoreková S, Pastorek J, Parkkila SM, Haapasalo HK: Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res; 2006 Jan 15;12(2):473-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.
  • Ectopic CA IX expression has been observed in several tumors, whose normal counterparts do not express this enzyme.
  • Normal human brain tissue shows only slight or no expression of CA IX.
  • RESULTS: CA IX immunopositivity was observed in 284 cases of 362 (78%) tumors.
  • The CA IX immunoreactivity showed strong association with tumor malignancy grades (P < 0.0001).
  • Our results suggest that CA IX is a useful biomarker for predicting poor prognosis of astrocytic tumors.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Astrocytoma / enzymology. Biomarkers, Tumor / metabolism. Brain Neoplasms / enzymology. Carbonic Anhydrases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis. Cell Proliferation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local / enzymology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, Epidermal Growth Factor / metabolism. Survival Rate. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428489.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


8. Kitai R, Horita R, Sato K, Yoshida K, Arishima H, Higashino Y, Hashimoto N, Takeuchi H, Kubota T, Kikuta K: Nestin expression in astrocytic tumors delineates tumor infiltration. Brain Tumor Pathol; 2010 Apr;27(1):17-21
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in astrocytic tumors delineates tumor infiltration.
  • Nestin is an intermediate filament protein expressed in undifferentiated cells during central nervous system development, and glioma is known to be a highly infiltrative tumor.
  • We determined whether nestin was expressed in astrocytic tumors and could identify infiltrating tumor cells.
  • We screened 65 archival, paraffin-embedded adult astrocytic tumors using immunohistochemical staining and computerized overlaid photographs.
  • Normal biopsied brains and metastatic brain tumors were also examined.
  • The intensity of nestin expression corresponded to the tumor grade.
  • Overlaid images showed that nestin immunostaining delineated tumor invasion into adjacent gray and white matter.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Intermediate Filament Proteins / metabolism. Intermediate Filament Proteins / physiology. Nerve Tissue Proteins / metabolism. Nerve Tissue Proteins / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Child. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nestin. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425043.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


9. Mennel HD, Lell B: Ganglioside (GD2) expression and intermediary filaments in astrocytic tumors. Clin Neuropathol; 2005 Jan-Feb;24(1):13-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglioside (GD2) expression and intermediary filaments in astrocytic tumors.
  • The search of proliferation markers in astrocytic tumors that may serve as targets for therapeutic interventions, is in full progress.
  • Gangliosides are lipid-sugar compounds localized on the cell membrane that are thought to modify pertinent signals and, therefore, may influence a variety of functions in normal and pathologic conditions including those that act upon tumor growth.
  • Intracranial supratentorial astrocytic gliomas of the adult represent a tumor group, that may be divided into three grades of malignancy, the most anaplastic member being the glioblastoma.
  • In earlier investigations, it had been shown that there is a tendency towards formation of more simple members of the ganglioside family with ongoing malignancy of those tumors.
  • Yet, the results were only partly congruent and the correlation to tumor grades rather loose.
  • We, therefore, investigated the occurrence of triaose gangliosides within these tumors in situ by immunohistochemistry.
  • Thus, the conclusion must be drawn that the correlation of ganglioside patterns to the proliferation of astrocytic tumors is as poor as that of GFAP or vimentin expression, respectively.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gangliosides / metabolism. Intermediate Filaments / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696779.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin; 65988-71-8 / ganglioside, GD2
  •  go-up   go-down


10. Kato Y, Hayatsu N, Kaneko MK, Ogasawara S, Hamano T, Takahashi S, Nishikawa R, Matsutani M, Mishima K, Narimatsu H: Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors. Biochem Biophys Res Commun; 2008 May 16;369(4):1041-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors.
  • Keratan sulfate (KS) proteoglycans are expressed on a subpopulation of microglia in normal adult brain.
  • However, it has not been clarified whether KS is expressed in brain tumors and is involved in their malignancy.
  • In this study, 54 astrocytic tumors were investigated about KS-expression using Western-blot with 5D4.
  • KS was hardly detected by 5D4 in diffuse astrocytoma, suggesting that KS-expression is significantly expressed in malignant astrocytic tumors.
  • In immunohistochemistry, KS is highly expressed in cell surface of malignant astrocytic tumors.
  • Taken together, KS might be associated with the malignancy of astrocytic tumors, and be useful for a prognostic factor of astrocytic tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329383.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9056-36-4 / Keratan Sulfate
  •  go-up   go-down


11. Sharma S, Sharma MC, Gupta DK, Sarkar C: Angiogenic patterns and their quantitation in high grade astrocytic tumors. J Neurooncol; 2006 Aug;79(1):19-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic patterns and their quantitation in high grade astrocytic tumors.
  • BACKGROUND: The objectives of this study on high grade astrocytic tumors were (i) to establish differences, if any, between grades III & IV tumors among angiogenic parameters, both qualitative and quantitative, and (ii) to correlate angiogenic parameters with proliferation indices, namely T2a and MIB1 labeling indices.
  • DESIGN: Twenty nine consecutive cases of WHO grades III (11) and IV (18) astrocytic tumors diagnosed in the year-2004 were studied, using H&E and CD34, MIB1 and T2a immunostaining by streptavidin biotin technique.
  • Limited follow up data showed all recurrent grade IV tumors to be of glomeruloid type.
  • CONCLUSION: Increased angiogenesis in grade IV, as compared to grade III, astrocytic tumors is characterized by an increased number/density of vessels: an increase in vessels characterized by disproportionate lengthening and likely associated with the infiltrative properties of the tumors; and an increase in pliable, irregularly shaped or structured vessels.
  • Further studies are needed to determine the usefulness of the angiogenic parameters in the improved diagnosis (grading) and prognosis of astrocytic tumors.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / pathology. Brain Neoplasms / blood supply. Brain Neoplasms / pathology. Neovascularization, Pathologic
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807783.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Kotoula V, Cheva A, Barbanis S, Papadimitriou CS, Karkavelas G: hTERT immunopositivity patterns in the normal brain and in astrocytic tumors. Acta Neuropathol; 2006 Jun;111(6):569-78
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hTERT immunopositivity patterns in the normal brain and in astrocytic tumors.
  • Accumulating data about the impact of hTERT in astrocytic tumor carcinogenesis and recent evidence about its association with disease outcome prompt the evaluation of this molecule with methods applicable in routine pathology practice.
  • In this study, we investigated hTERT protein expression with immunohistochemistry (IHC) and the NCL-hTERT antibody in 49 astrocytic tumors.
  • Low- and high-grade astrocytic tumors were found positive for hTERT in 74 and 85% of cases, respectively.
  • Heterogeneity in the distribution of hTERT-positive cells was observed in all tumors.
  • Positive endothelial cells were found in astrocytic tumors of all grades, even when tumor cells showed no hTERT immunoreactivity.
  • A subset of mature normal neurons was positive for hTERT (pattern As), suggesting a role for this molecule in neuronal maintenance in the adult brain.
  • The nuclear hTERT IPs described here may reflect the functional status of non-neoplastic brain and neoplastic astrocytic cells and support the model of a continuum in the development of glioblastomas from diffuse fibrillary astrocytomas.
  • [MeSH-major] Astrocytes / metabolism. Astrocytoma / metabolism. Brain Chemistry / physiology. Brain Neoplasms / metabolism. Telomerase / genetics. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Child. Endothelial Cells / pathology. Female. Fixatives. Formaldehyde. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Paraffin Embedding. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614861.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fixatives; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 1HG84L3525 / Formaldehyde; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


13. Li X, Wang Y, Wang Y, Zhen H, Yang H, Fei Z, Zhang J, Liu W, Wang Y, Zhang X: Expression of EphA2 in human astrocytic tumors: correlation with pathologic grade, proliferation and apoptosis. Tumour Biol; 2007;28(3):165-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of EphA2 in human astrocytic tumors: correlation with pathologic grade, proliferation and apoptosis.
  • A high expression of EphA2 has been detected in many non-central nervous system tumors; however, the EphA2 expression in brain astrocytic tumors remains unclear.
  • In this study, we investigated the expression of EphA2 mRNA and protein in 90 cases of human astrocytic tumors by reverse transcription polymerase chain reaction and immunohistochemistry, respectively.
  • The proliferative index (PI) of tumor cells was evaluated by Ki-67 immunohistochemistry, and the apoptotic index (AI) was determined by TdT-mediated dUTP nick end labeling assay.
  • The correlation between EphA2 expression, pathologic grade, proliferation and apoptosis of astrocytic tumors was further analyzed.
  • Therefore, EphA2 may be a new biomarker for astrocytic tumors.
  • It may also affect the proliferation and apoptosis of tumor cells and be an attractive therapy target for astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Receptor, EphA2 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis. Cell Division. Child. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17519535.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, EphA2
  •  go-up   go-down


14. Murakami H, Sawa H, Kamada H: [Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors]. No To Shinkei; 2006 Jan;58(1):43-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of cyclooxygenase (COX)-2 in astrocytic tumors and anti-tumor effects of selective COX-2 inhibitors].
  • Cyclooxygenase (COX)-2 of astrocytic tumors was studied by immunohistochemistry.
  • The result showed that COX-2 expression may be related with histological grades and COX-2 inhibitors will be one of promising therapeutic tools in human astrocytic tumors.
  • [MeSH-minor] Adult. Aged. Etodolac / pharmacology. Female. Glioblastoma / drug therapy. Glioblastoma / enzymology. Humans. Immunoblotting. Immunohistochemistry. Male. Middle Aged. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482921.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; 2M36281008 / Etodolac; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


15. Ren ZP, Olofsson T, Qu M, Hesselager G, Soussi T, Kalimo H, Smits A, Nistér M: Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. J Neuropathol Exp Neurol; 2007 Oct;66(10):944-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.
  • We investigated genetic heterogeneity of astrocytic gliomas using p53 gene mutations as a marker.
  • Different parts of morphologically heterogeneous astrocytic gliomas were microdissected, and direct DNA sequencing of p53 gene exons 5 through 8 was performed.
  • Thirty-five glioma samples and tumor-adjacent normal-appearing brain tissue from 11 patients were analyzed.
  • We found that some tumors were devoid of p53 gene mutations, whereas other tumors carried 1 or often several (up to 3) different mutations.
  • The mutations were present in grade II, III, and IV astrocytic glioma areas.
  • Both severe functionally dead mutants and mutants with remaining transcriptional activity could be observed in the same tumor.
  • These results support the notion that intratumoral heterogeneity in brain tumors originates from different molecular defects.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genes, p53 / genetics
  • [MeSH-minor] Adult. Aged. DNA Primers. DNA, Neoplasm / genetics. Female. Gene Frequency. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Microdissection. Middle Aged. Mutation / genetics. Mutation / physiology. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917588.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm
  •  go-up   go-down


16. Higano S, Yun X, Kumabe T, Watanabe M, Mugikura S, Umetsu A, Sato A, Yamada T, Takahashi S: Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology; 2006 Dec;241(3):839-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis.
  • PURPOSE: To retrospectively assess the apparent diffusion coefficient (ADC) for prediction of malignancy and prognosis of malignant astrocytic tumors.
  • Findings from 37 consecutive patients (21 men, 16 women; mean age, 43 years) with pathologically proved malignant astrocytic tumors that included 22 glioblastomas (GBMs) and 15 anaplastic astrocytomas (AAs) were retrospectively evaluated.
  • The minimum ADC value of each tumor was preoperatively determined from several regions of interest defined in the tumor, preferably with avoidance of cystic or necrotic components, on ADC maps derived from isotropic diffusion-weighted images.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Humans. Image Processing, Computer-Assisted. Ki-67 Antigen / analysis. Male. Predictive Value of Tests. Prognosis. ROC Curve. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006.
  • (PMID = 17032910.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


17. Ido K, Nakagawa T, Sakuma T, Takeuchi H, Sato K, Kubota T: Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumors. Neuropathology; 2008 Dec;28(6):604-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumors.
  • High-grade astrocytic tumors, such as glioblastoma, possess rich vascular components, which are necessary for their growth.
  • VEGF-A is considered to be the major mediator of angiogenesis in malignant neoplasms including high-grade astrocytic tumors.
  • The upregulation of VEGF-A expression in tumor cells is induced by two mechanisms: the transcriptional activation and the post-transcriptional stabilization of VEGF-A mRNA.
  • While the former mechanism mediated by hypoxia inducible factor-1 alpha (HIF-1alpha) has been revealed, the latter mediated by mRNA stability factor HuR remains unclear in astrocytic tumors.
  • In the present study, we investigated the expression of VEGF-A and mRNA stability factor HuR in supratentorial astrocytic tumors of 27 adults using RT-PCR, ELISA, and immunohistochemistry.
  • In higher-grade astrocytic tumors, the level of VEGF-A and microvascular density were elevated, cytoplasmic expression of HuR, which potentially means the protection of VEGF-A mRNA from degradation by ribonucleases, appeared, and they were correlated positively.
  • In in vitro experiments, the inhibition of the cytoplasmic translocation of HuR protein by leptomycin B (LMB) reduced the upregulation of VEGF-A expression in malignant astrocytic tumor cells under hypoxic conditions.
  • These findings suggest that the expression of VEGF-A and cytoplasmic translocation of HuR relates to the histological grade, and that HuR is involved in the upregulation of VEGF-A expression, in human astrocytic tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiogenesis Inducing Agents. Cytoplasm / metabolism. ELAV Proteins. ELAV-Like Protein 1. Enzyme-Linked Immunosorbent Assay. Fatty Acids, Unsaturated / pharmacology. Female. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Male. Middle Aged. RNA Processing, Post-Transcriptional. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Up-Regulation. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498284.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / Fatty Acids, Unsaturated; 0 / RNA-Binding Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 87081-35-4 / leptomycin B
  •  go-up   go-down


18. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germanò A, Vita G, Tomasello F: miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol; 2009 Jul;93(3):325-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.
  • Recent evidence indicates that miRNAs can function both as tumor suppressors and as oncogenes.
  • Expression of miR-21, 221, 128a, 128b, 128c, 181a, 181b, 181c was studied using real-time quantitative reverse transcriptase polymerase chain reaction and northern blotting for human astrocytic tumors with different grade of malignancy. miR-21 and 221 were overexpressed in glioma samples, whereas miRNA 181b was downregulated compared with normal brain tissue. miRNA-21 was hyperexpressed in all tumor samples whereas higher levels of miRNA-221 were found in high-grade gliomas.
  • This study is the first analysis of miRNAs in astrocytic tumor at different stages of malignancy.
  • The different expression pattern observed in tumors at different stages of malignancy is probably dependent on the cell-specific repertoire of target genes of tumors sharing different molecular pathways activity and suggests miRNAs may have also a place in diagnosis and staging of brain tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. MicroRNAs / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Northern. Down-Regulation. Female. Gene Expression. Gene Expression Profiling. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19159078.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN21 microRNA, human; 0 / MIRN221 microRNA, human; 0 / MIrn181 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


19. Faria MH, Gonçalves BP, do Patrocínio RM, de Moraes-Filho MO, Rabenhorst SH: Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology; 2006 Dec;26(6):519-27
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
  • Astrocytomas represent the most frequent primary tumors of the central nervous system.
  • Recently, the determination of the proliferative index of astrocytic tumors by different methods has been proposed as a valuable tool for tumor grading and also as a prognostic marker.
  • The aim of the present study was to evaluate the expression of cell proliferation-related proteins in human astrocytic tumors of different histopathological grades (WHO).
  • An immunohistochemical study of the Ki-67, Topoisomerase IIalpha (Topo IIalpha) and c-MYC proteins using the avidin-biotin-peroxidase method was performed in 55 astrocytomas (13 grade I, 14 grade II, 7 grade III and 21 grade IV) and five samples of non-tumor brain tissue (control group).
  • Ki-67, Topo IIalpha and c-MYC positive indices tended to increase according to malignant progression, were absent in non-tumor brain tissue and showed maximum values in high-grade astrocytomas (III and IV).
  • Ki-67 antigen detection in more than 8.0% of the tumor cells distinguished astrocytoma grade IV, while a labeling index between 1.5 and 8.0% characterized astrocytomas grade III and values below 1.5% discriminated low-grade tumors (I and II).
  • Moreover, Ki-67 antigen was found to be the best marker of cellular proliferation, and its expression predicts the grade of astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Cell Division. Child. Child, Preschool. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Female. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Infant. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins c-myc / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203587.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-myc; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


20. Laywell ED, Steindler DA, Silver DJ: Astrocytic stem cells in the adult brain. Neurosurg Clin N Am; 2007 Jan;18(1):21-30, viii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Astrocytic stem cells in the adult brain.
  • The adult mammalian brain harbors a population of neural stem cells (NSCs) that are responsible for persistent neurogenesis in the olfactory system and hippocampus and may also play a role in tumorigenesis.
  • Here, the authors review the evidence that NSCs within the adult brain are a special type of astrocyte.
  • Finally, the authors compare and contrast the functional characteristics of NSCs and hematopoietic stem cells and review the potential oncogenic transformation of astrocyte NSCs that may underlie brain tumorigenesis as seen in glioblastoma and other primary brain tumors.
  • [MeSH-major] Adult Stem Cells / cytology. Astrocytes / cytology. Dentate Gyrus / cytology. Ependyma / cytology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244551.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL070143; United States / NINDS NIH HHS / NS / NS37556
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


21. Erdamar S, Bagci P, Oz B, Dirican A: Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON; 2006 Apr-Jun;11(2):213-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
  • PURPOSE: Many characteristics of malignant brain tumors (increased vascular permeability, vasodilatation, neovascularisation and free radical injury to the tumor and adjacent normal tissues) are believed to be mediated by nitric oxide (NO) synthetized by endothelial NO synthase (eNOS).
  • Overexpression of vascular endothelial growth factor (VEGF) is associated with several central nervous system (CNS) diseases and tumors.
  • Our aim was to study immunohistochemically the coexpression of eNOS and VEGF in astrocytic tumors and to analyse their possible correlation with tumor grade, angiogenesis and proliferation index.
  • MATERIALS AND METHODS: Sections from 120 randomly selected patients with supratentorial astrocytic tumors [38 glioblastomas (GB), 22 anaplastic astrocytomas (AA) and 20 low-grade astrocytomas (LA)], also including oligodendrogliomas (n=20) and mixed oligoastrocytomas (n=20), were immunostained with monoclonal antibodies for eNOS and VEGF using the avidin-biotin method.
  • The proliferative potential was assessed as the MIB-1 staining index for tumor cells.
  • CONCLUSION: Overexpressions of eNOS and VEGF in astrocytic tumors were significantly correlated with histological grade, proliferative potential and malignant transformation.
  • The expression of VEGF in a necrotic and ischemic tumor such as GB is more intense and diffuse than low-grade astrocytomas.
  • These findings suggest that eNOS overexpression in tumor vasculature would be precipitated by transformation into an angiogenic phenotype in the process of neovascularisation in astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Nitric Oxide Synthase Type III / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Humans. Immunohistochemistry. Middle Aged. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318973.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


22. Tan G, Sun SQ, Yuan DL: Expression of Kir 4.1 in human astrocytic tumors: correlation with pathologic grade. Biochem Biophys Res Commun; 2008 Mar 21;367(4):743-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Kir 4.1 in human astrocytic tumors: correlation with pathologic grade.
  • In this study, we investigated the expression of Kir 4.1 mRNA and protein in 80 cases of human astrocytic tumors by reverse transcription polymerase chain reaction, Western blot and immunohistochemistry, respectively.
  • The correlation between Kir 4.1 expression and pathologic grade of astrocytic tumors was further analyzed.
  • Therefore, Kir 4.1 may be a new biomarker for astrocytic tumors.
  • It may also be an attractive therapy target for human astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Neoplasm Proteins / metabolism. Potassium Channels, Inwardly Rectifying / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Statistics as Topic. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18191638.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Kcnj10 (channel); 0 / Neoplasm Proteins; 0 / Potassium Channels, Inwardly Rectifying
  •  go-up   go-down


23. Ritch PS, Carroll SL, Sontheimer H: Neuregulin-1 enhances survival of human astrocytic glioma cells. Glia; 2005 Aug 15;51(3):217-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuregulin-1 enhances survival of human astrocytic glioma cells.
  • Malignant astrocytic gliomas, referred to as astrocytomas, represent the most commonly diagnosed adult primary brain tumor.
  • These tumors are characterized by unrelenting growth that is often resistant to chemotherapy and radiation therapy.
  • Tumor expansion into the healthy surrounding brain tissue produces severe and often fatal consequences.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1992 Sep;7(9):1859-66 [1354348.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):106-15 [7689190.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):492-500 [8264617.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1064-8 [8302832.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1909-19 [7509448.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3550-8 [7515147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9387-91 [7937775.001]
  • [Cites] Biochim Biophys Acta. 1994 Dec 30;1198(2-3):165-84 [7819273.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1403-11 [7731691.001]
  • [Cites] J Cell Biol. 1995 Jul;130(1):127-35 [7540614.001]
  • [Cites] J Biol Chem. 1995 Aug 11;270(32):19188-96 [7642587.001]
  • [Cites] Neuron. 1996 Aug;17(2):229-43 [8780647.001]
  • [Cites] Mol Cell Neurosci. 1996 Apr;7(4):247-62 [8793861.001]
  • [Cites] EMBO J. 1997 Apr 1;16(7):1647-55 [9130710.001]
  • [Cites] Nature. 1997 May 29;387(6632):509-12 [9168114.001]
  • [Cites] Nature. 1997 May 29;387(6632):512-6 [9168115.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):4007-14 [9199335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9562-7 [9275162.001]
  • [Cites] J Neurochem. 1997 Nov;69(5):1859-63 [9349528.001]
  • [Cites] J Neurosci Res. 1997 Dec 1;50(5):755-68 [9418963.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):193-209 [9440020.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):223-48 [9440022.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):335-46 [9440030.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1825-36 [9637684.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):757-63 [9677338.001]
  • [Cites] Biochem J. 1998 Oct 1;335 ( Pt 1):1-13 [9742206.001]
  • [Cites] Can J Neurol Sci. 1998 Nov;25(4):267-81 [9827227.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] Eur J Neurosci. 1999 Mar;11(3):769-80 [10103071.001]
  • [Cites] Mol Cell Neurosci. 1999 Feb;13(2):79-94 [10192767.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2681-9 [10348342.001]
  • [Cites] EMBO J. 1994 Jun 15;13(12):2831-41 [8026468.001]
  • [Cites] Adv Cancer Res. 2000;77:25-79 [10549355.001]
  • [Cites] Glia. 2000 Jan 15;29(2):104-11 [10625327.001]
  • [Cites] Toxicol Pathol. 2000 Jan-Feb;28(1):171-7 [10669005.001]
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:561-76 [10698680.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] J Neurosci. 2000 Oct 15;20(20):7622-30 [11027222.001]
  • [Cites] Bioessays. 2000 Nov;22(11):987-96 [11056475.001]
  • [Cites] Brain Res Dev Brain Res. 2000 Nov 30;124(1-2):93-9 [11113516.001]
  • [Cites] Annu Rev Neurosci. 2001;24:385-428 [11283316.001]
  • [Cites] Neuro Oncol. 2000 Apr;2(2):96-102 [11303626.001]
  • [Cites] Mol Cell Neurosci. 2001 Apr;17(4):761-7 [11312610.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2841-51 [11042203.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7320-6 [11058599.001]
  • [Cites] Curr Opin Neurobiol. 2001 Jun;11(3):287-96 [11399426.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] J Neurosci. 2001 Jul 1;21(13):4740-51 [11425901.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):683-8 [11723374.001]
  • [Cites] Fed Proc. 1983 Jun;42(9):2627-9 [6852276.001]
  • [Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]
  • [Cites] Cell. 1985 Jul;41(3):697-706 [2860972.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] Cell. 1986 Jun 6;45(5):649-57 [2871941.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):3910-8 [2454731.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):681-94 [2685640.001]
  • [Cites] J Neurosurg. 1991 Aug;75(2):284-93 [1649272.001]
  • [Cites] Ann N Y Acad Sci. 1991;633:35-47 [1789559.001]
  • [Cites] Cell. 1992 Apr 3;69(1):205-16 [1348215.001]
  • [Cites] J Neurosci Res. 1992 Jan;31(1):175-87 [1377283.001]
  • (PMID = 15812817.001).
  • [ISSN] 0894-1491
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097247-010003; United States / NINDS NIH HHS / NS / R01 NS036692-05A1; United States / NCI NIH HHS / CA / CA097247-010003; United States / NCI NIH HHS / CA / P50 CA097247; United States / NCI NIH HHS / CA / P50CA97247; United States / NINDS NIH HHS / NS / NS036692-05A1; United States / NINDS NIH HHS / NS / R01 NS036692; United States / NINDS NIH HHS / NS / R01-NS36692; United States / NINDS NIH HHS / NS / R01 NS036692-06; United States / NINDS NIH HHS / NS / NS036692-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuregulin-1; 0 / Protein Subunits; 0 / Proto-Oncogene Proteins; 0 / Recombinant Fusion Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.10.1 / Receptor, ErbB-4; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS25075; NLM/ PMC2548407
  •  go-up   go-down


24. Yao Y, Kubota T, Takeuchi H, Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology; 2005 Sep;25(3):201-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
  • There are conflicting reports as to whether the degree of angiogenesis as measured by microvessel density (MVD) has a prognostic value in astrocytic tumors.
  • To clarify the validity of anti-CD105 antibody in the evaluation of angiogenesis, we assessed MVD using an anti-CD105 monoclonal antibody (mAb) (CD105-MVD) and an anti-CD31 mAb (CD31-MVD) in a series of 50 astrocytic tumors, and correlated MVD with expression of the key angiogenic factor vascular endothelial growth factor (VEGF) and prognosis.
  • Patients with LGA and GBM showing higher CD105-MVD had a significantly shorter mean survival time (MST) than those with lower CD105-MVD tumors (P = 0.0381 and 0.0131, respectively).
  • Whereas the MST of patients with higher CD31-MVD tumors seemed to be shorter than that of lower CD31-MVD patients within each tumor grade, the differences were not statistically significant.
  • These findings suggest that anti-CD105 mAb may be a better marker than anti-CD31 mAb in evaluation of angiogenesis and prediction of prognosis in astrocytic tumors.
  • [MeSH-major] Antibodies, Monoclonal. Astrocytoma / blood supply. Biomarkers, Tumor / analysis. Brain Neoplasms / mortality. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD. Antigens, CD31 / biosynthesis. Antigens, CD31 / immunology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Receptors, Cell Surface. Survival Analysis. Survival Rate. Vascular Cell Adhesion Molecule-1 / biosynthesis. Vascular Cell Adhesion Molecule-1 / immunology. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193836.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Vascular Cell Adhesion Molecule-1; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


25. Jin S, Sun C, Yu S, Wang Q, Wu W, Sun Y, Zhao W, An T: Chromosome DNA imbalances in human astrocytic tumors: a comparative genomic hybridization study of 63 Chinese patients. Pathol Res Pract; 2010 Oct 15;206(10):674-81
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome DNA imbalances in human astrocytic tumors: a comparative genomic hybridization study of 63 Chinese patients.
  • Astrocytic tumors are the most frequent primary brain neoplasms.
  • Analysis of chromosome DNA imbalance may help to advance diagnosis, grading, and classification, and to determine appropriate therapeutic approaches for tumors of astrocytic lineages.
  • Comparative genomic hybridization (CGH) provides comprehensive information about chromosome DNA aberrations, and is an important technique for evaluating the differences at genomic levels among the same or different grade tumors.
  • In this study, 63 astrocytic tumors of Chinese patients were screened by CGH, and the relationship between their chromosome DNA imbalances and the histopathological classification, grading, and clinical features was analyzed.
  • Most tumors showed genomic copy aberrations detected by CGH.
  • This study confirmed that chromosomal aberrations, such as +1q, -4q, -10q, +7p, and -15q possibly contributed to the pathogenesis of these tumors.
  • Our data was the first report on the chromosomal aberrations of astrocytic tumors of Chinese patients.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Comparative Genomic Hybridization. Glioblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. China. Female. Gene Expression Regulation, Neoplastic. Genotype. Humans. Male. Middle Aged. Neoplasm Staging. Phenotype. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20591577.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


26. Murakami R, Hirai T, Sugahara T, Fukuoka H, Toya R, Nishimura S, Kitajima M, Okuda T, Nakamura H, Oya N, Kuratsu J, Yamashita Y: Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology; 2009 Jun;251(3):838-45
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method.
  • PURPOSE: To assess the utility of both minimum apparent diffusion coefficients (ADCs) and ADC difference values for grading astrocytic tumors at magnetic resonance imaging.
  • Fifty patients (23 male patients, 27 female patients; median age, 53 years) with newly diagnosed astrocytic tumors were evaluated.
  • Two observers blinded to clinical information independently measured the ADCs by manually placing three to five regions of interest (40-60 mm(2)) within the solid tumor either with or without contrast material-enhanced components and calculated the average ADC.
  • These ADC values were used as the parameters for tumor grading and were compared by using the Kruskal-Wallis test and receiver operating characteristic (ROC) curve analysis.
  • RESULTS: According to ROC analyses for distinguishing tumor grade, minimum ADCs showed the largest areas under the ROC curve.
  • Minimum ADCs optimally helped distinguish grade 1 from higher-grade tumors at a cutoff value of 1.47 x 10(-3) mm(2)/sec and grade 4 from lower-grade tumors at a cutoff value of 1.01 x 10(-3) mm(2)/sec (P < .001 for both).
  • ADC difference values helped distinguish grade 2 from grade 3 tumors at a cutoff value of 0.31 x 10(-3) mm(2)/sec (P < .001).
  • When tumors were graded by using the combined minimum ADC and ADC difference cutoff values mentioned above (the two-parameter method), the following positive predictive values were obtained: grade 1 tumors, 73% (eight of 11); grade 2 tumors, 100% (five of five); grade 3 tumors, 67% (eight of 12); and grade 4 tumors, 91% (20 of 22).
  • CONCLUSION: Using a combination of minimum ADCs and ADC difference values (the two-parameter method) facilitates the accurate grading of astrocytic tumors.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Contrast Media. Female. Gadolinium DTPA. Humans. Image Interpretation, Computer-Assisted. Male. Middle Aged. Neoplasm Staging. Pilot Projects. ROC Curve. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318585.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


27. Combs SE, Nagy M, Edler L, Rausch R, Bischof M, Welzel T, Debus J, Schulz-Ertner D: Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. Radiother Oncol; 2008 Aug;88(2):177-82
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors.
  • Outcome after radiochemotherapy (RCHT) with temozolomide (TMZ) versus radiotherapy (RT) for WHO grade III astrocytic tumors was evaluated.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395280.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


28. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, Henriksson R: Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol; 2006 Mar;111(3):238-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.
  • We have previously characterized three human leucine-rich repeats and immunoglobulin-like domains (LRIG) genes and proteins, named LRIG1-3 and proposed that they may act as suppressors of tumor growth.
  • In this study, we evaluated the mRNA expression level of LRIG1-3 in human glioma cell lines and control-matched glioma tissues, characterized the sub-cellular localization of an LRIG3-GFP fusion protein, and analyzed the relationship between sub-cellular localization of LRIG1-3 and clinical parameters in 404 astrocytic tumors by immunohistochemistry.
  • Perinuclear staining of LRIG3 was associated with a lower proliferation index and was in addition to tumor grade, an independent prognostic factor.
  • Furthermore, within the groups of grade III and grade IV tumors, perinuclear staining of LRIG3 significantly correlated with better survival.
  • These results indicate that expression and sub-cellular localization of LRIG1-3 might be of importance in the pathogenesis and prognosis of astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Proliferation. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Survival Rate


29. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K: Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol; 2010 Dec;100(3):449-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis.
  • Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) is a multifunctional protein that was first identified in brain astrocytes and that has subsequently been shown to be expressed in different tissues.
  • Despite its many important roles, the clinical significance of PEA-15 expression levels in astrocytic tumors has yet to be properly defined.
  • All tumors expressed PEA-15 in our study.
  • Twenty-three (35.4%) and 42 (64.6%) tumors expressed low and high PEA-15 levels, respectively.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Phosphoproteins / metabolism. Statistics as Topic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Severity of Illness Index. Statistics, Nonparametric. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Health Statistics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20455002.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / PEA15 protein, human; 0 / Phosphoproteins
  •  go-up   go-down


30. Plotkin M, Amthauer H, Eisenacher J, Wurm R, Michel R, Wust P, Stockhammer F, Röttgen R, Gutberlet M, Ruf J, Felix R: Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours. Neuroradiology; 2005 Jan;47(1):18-26
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.
  • In the current study we investigated whether IMT-SPECT could also be useful in the follow-up of brain metastases and other intracranial tumours of non-astrocytic origin.
  • The study included 22 patients with suspected recurrent intracranial tumours of non-astrocytic origin (12 brain metastases, one supratentorial primitive neuroendocrine tumour (PNET), one rhabdoid tumour, two clivus chordomas, three ependymomas, two pituitary tumours, one anaplastic meningioma) who had previously been treated by surgery and/or radio/chemotherapy.
  • We concluded that the IMT-SPECT is a promising complementary imaging tool for the detection of recurrences of non-astrocytic intracranial tumours and their distinguishing from treatment-induced changes.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Iodine Radioisotopes. Methyltyrosines. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Chordoma / radionuclide imaging. Ependymoma / radionuclide imaging. False Negative Reactions. False Positive Reactions. Female. Follow-Up Studies. Glioma / radionuclide imaging. Humans. Magnetic Resonance Imaging. Male. Meningioma / radionuclide imaging. Middle Aged. Neuroendocrine Tumors / radionuclide imaging. Pituitary Neoplasms / radionuclide imaging. Retrospective Studies. Rhabdoid Tumor / radionuclide imaging. Sensitivity and Specificity. Supratentorial Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15630586.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Methyltyrosines; 0 / Radiopharmaceuticals; 14684-02-7 / 3-iodo-alpha-methyltyrosine
  •  go-up   go-down


31. McCarthy BJ, Propp JM, Davis FG, Burger PC: Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology; 2008;30(1):34-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trends in oligodendroglial and astrocytic tumor incidence.
  • BACKGROUND: We hypothesized that the incidences of oligodendrogliomas, anaplastic oligodendrogliomas, and mixed gliomas have significantly increased from the early 1990 s forward, while the incidences of anaplastic and grade II astrocytic tumors have significantly decreased.
  • METHODS: Data for the years 1973-2004 from the Surveillance, Epidemiology and End Results (SEER) public-use data and for 1985-2004 from six collaborating registries of the Central Brain Tumor Registry of the US (CBTRUS) were obtained.
  • CONCLUSIONS: This study has demonstrated that increases in oligodendroglial tumor incidence correspond to decreases in astrocytic tumor incidence over the same time period.
  • Minimizing misclassification of glial tumors will be essential for accurately assessing incidence, survival, and mortality rates, as well as for identifying homogeneous subgroups for epidemiologic and treatment studies.
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Glioma / epidemiology. Oligodendroglioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Humans. Incidence. Infant. Infant, Newborn. Middle Aged. Registries / statistics & numerical data. Time. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18259099.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


32. Choi KC, Kwak SE, Kim JE, Sheen SH, Kang TC: Enhanced glial fibrillary acidic protein-delta expression in human astrocytic tumor. Neurosci Lett; 2009 Oct 9;463(3):182-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced glial fibrillary acidic protein-delta expression in human astrocytic tumor.
  • Astrocytic tumor is one of the most common primary tumors of the adult brain.
  • Although there are several biochemical markers for the categorization of astrocytic tumor, few markers are used for histopathological diagnosis.
  • In tissue samples from patients with low-grade astrocytic tumor (grades I and II), GFAP-delta(+) cells appeared stellate, polygonal or round shape.
  • In tissue samples from patients with high-grade astrocytic tumor (grades III and IV), GFAP-delta(+) cells showed round or spindle shape.
  • GFAP-delta immunoreactivities in grades III and IV astrocytic tumor cells were increased by 1.4- and 1.7-fold in comparison to grade I astrocytic tumor cells.
  • GFAP-delta immunoreactivity was also observed in cell bodies along the margins of astrocytic tumor showing normal histological findings, even though astroglia had normal morphology (showing strong GFAP and glutamine synthase immunoreactivities and a stellate shape with well-developed processes).
  • Furthermore, the malignancy of astrocytic tumor was directly correlated with the degree of GFAP-delta immunoreactivity.
  • These findings suggest that GFAP-delta may be a useful diagnostic marker for the evaluation of functional cataplasia or proliferation of astrocytic tumor.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / biosynthesis. Brain Neoplasms / metabolism. Glial Fibrillary Acidic Protein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Alternative Splicing. Child. Female. Glutamate-Ammonia Ligase / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647039.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; EC 6.3.1.2 / Glutamate-Ammonia Ligase
  •  go-up   go-down


33. Huang X, Bai HM, Chen L, Li B, Lu YC: Reduced expression of LC3B-II and Beclin 1 in glioblastoma multiforme indicates a down-regulated autophagic capacity that relates to the progression of astrocytic tumors. J Clin Neurosci; 2010 Dec;17(12):1515-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of LC3B-II and Beclin 1 in glioblastoma multiforme indicates a down-regulated autophagic capacity that relates to the progression of astrocytic tumors.
  • The aim of this study was to investigate the expression of microtubule-associated protein 1 light chain 3B (LC3B) and the autophagy-related gene Beclin 1 in astrocytic tumors and to analyze their expression profiles with respect to the development of astrocytic tumors.
  • The expression patterns of LC3B and Beclin 1 were analyzed by immunohistochemistry and/or western blotting in tumor samples from 62 patients with different grades of astrocytic tumor.
  • Western blot analysis indicated that the average optical densitometry (OD) ratio of Beclin 1 in high-grade astrocytic tumors (World Health Organization [WHO] grade III/IV) was lower than in low-grade astrocytic tumors (WHO grade I/II, p = 0.036).
  • The expression of LC3B-I exhibited no significant difference among the various grades of astrocytic tumor.
  • However, the average OD ratio of LC3B-II was lower in glioblastoma multiforme (GBM) than in other grades of astrocytic tumor (p = 0.030).
  • The progression of astrocytic tumors was related to a decrease in autophagic capacity represented by the loss of LC3B-II and Beclin 1 expression.
  • [MeSH-major] Apoptosis Regulatory Proteins / biosynthesis. Brain Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Glioblastoma / pathology. Membrane Proteins / biosynthesis. Microtubule-Associated Proteins / biosynthesis
  • [MeSH-minor] Adult. Astrocytoma / metabolism. Astrocytoma / pathology. Autophagy. Blotting, Western. Disease Progression. Down-Regulation. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20863706.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BECN1 protein, human; 0 / Membrane Proteins; 0 / Microtubule-Associated Proteins; 0 / light chain 3, human
  •  go-up   go-down


34. Yoo H, Sohn S, Nam BH, Min HS, Jung E, Shin SH, Gwak HS, Lee SH: The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis. Int J Mol Med; 2010 Jul;26(1):3-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis.
  • Hypoxia in the tumor microenvironment triggers a variety of genetic and adoptive responses that regulate tumor growth.
  • Tumor hypoxia is often associated with a malignant phenotype, resistance to therapy, and poor survival.
  • The objectives of this study were to evaluate the expressions of carbonic anhydrase 9 (CA9) and vascular endothelial growth factor (VEGF) in astrocytic gliomas and to relate patterns of expression with prognosis, that is with histological grade and survival.
  • We investigated 78 World Health Organization (WHO) grade II, III, and IV astrocytic gliomas.
  • Fourteen tumors were grade II, 30 were grade III, and 34 were grade IV.
  • There were 3 CA9 positive tumors in grade II (21.4%), 10 in grade III (33.3%), and 27 in grade IV (79.4%).
  • For all tumors and WHO grade II, overall survival was found to be significantly dependent on CA9 expression (p=0.004, p=0.01).
  • Furthermore, VEGF expression was found to be significantly related to tumor grade (p=0.02) and tended to be related to overall survival (p=0.1).
  • Nevertheless, the expressions of CA9 and VEGF were found to be associated with tumor grade and possibly with survival.
  • Further studies on a larger patient population are needed to determine the correlation between the expressions of CA9, and VEGF in astrocytic gliomas and clinical outcome.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Astrocytoma / metabolism. Carbonic Anhydrases / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry / statistics & numerical data. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514415.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Vascular Endothelial Growth Factor A; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


35. Shukla B, Agarwal S, Suri V, Pathak P, Sharma MC, Gupta D, Sharma BS, Suri A, Halder A, Sarkar C: Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurol India; 2009 Sep-Oct;57(5):559-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
  • Astrocytomas and the astrocytic component of oligoastrocytomas showed a diffuse fibrillary type of staining.
  • CONCLUSION: Loss of 1p/19q is strongly associated with oligodendroglial phenotype, while astrocytic tumors are more likely to show p53 over-expression. p53 expression and 1p/19q status appear to be mutually exclusive.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosomes, Human, Pair 19. In Situ Hybridization, Fluorescence / methods. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / metabolism. Retrospective Studies. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934553.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


36. Mabrouk GM, Ali EM, El-Rehany MA, El-Samoly HM: TGF-beta1, TNF-alpha and cytochrome c in human astrocytic tumors: a short-term follow up and correlation with survival. Clin Biochem; 2007 Feb;40(3-4):255-60
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGF-beta1, TNF-alpha and cytochrome c in human astrocytic tumors: a short-term follow up and correlation with survival.
  • DESIGN AND METHODS: We measured TGF-beta1, TNF-alpha and cytoplasmic cytochrome c in 30 astrocytic tumors Grade II, III and IV.
  • Patients with astrocytic tumors having elevated cytochrome c showed a better survival rate compared to those with less release.
  • [MeSH-major] Astrocytoma / diagnosis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Cytochromes c / analysis. Transforming Growth Factor beta1 / analysis. Tumor Necrosis Factor-alpha / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070791.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Transforming Growth Factor beta1; 0 / Tumor Necrosis Factor-alpha; 9007-43-6 / Cytochromes c
  •  go-up   go-down


37. Jha P, Agarwal S, Pathak P, Srivastava A, Suri V, Sharma MC, Chosdol K, Srivastava T, Gupta D, Gupta A, Suri A, Sarkar C: Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. Cancer Genet Cytogenet; 2010 Apr 15;198(2):126-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
  • There are few reports of loss of heterozygosity (LOH) of 1p and 19q in astrocytic tumors, especially glioblastoma multiforme (GBM).
  • Thus, 1p and 19q LOH can occur in astrocytic tumors, most commonly in secondary GBMs without morphological correlation with an oligodendroglial histology.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Gene Amplification. Genes, erbB-1. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Child. Female. Heterozygote. Humans. India. Loss of Heterozygosity. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20362227.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


38. Ono A, Kanno H, Hayashi A, Nishimura S, Kyuma Y, Sato H, Ito S, Shimizu N, Chang CC, Gondo G, Yamamoto I, Sasaki T, Tanaka M: Collagen gel matrix assay as an in vitro chemosensitivity test for malignant astrocytic tumors. Int J Clin Oncol; 2007 Apr;12(2):125-30
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen gel matrix assay as an in vitro chemosensitivity test for malignant astrocytic tumors.
  • METHODS: We examined the chemosensitivites for four anticancer agents - 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3 (2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), carboplatin, cisplatin, and etoposide - of 43 malignant astrocytic tumors (21 anaplastic astrocytomas and 22 glioblastomas) by using a collagen gel matrix assay, and we also determined the survival periods of the tumor-bearing patients.
  • Individual chemotherapy for malignant astrocytic tumors, based on chemosensitivity data, could contribute to longer survival, particularly in anaplastic astrocytoma-bearing patients.
  • [MeSH-minor] Adult. Aged. Central Nervous System Neoplasms / drug therapy. Disease Progression. Disease-Free Survival. Drug Screening Assays, Antitumor. Female. Fibrin Foam. Follow-Up Studies. Glioblastoma / drug therapy. Glioblastoma / pathology. Humans. Japan. Karnofsky Performance Status. Male. Middle Aged. Sensitivity and Specificity. Survival Analysis. Tissue Adhesives. Treatment Outcome. Tumor Burden / drug effects. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443280.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fibrin Foam; 0 / Tissue Adhesives; 0S726V972K / Nimustine; 6PLQ3CP4P3 / Etoposide; 9007-34-5 / Collagen; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


39. Fountzilas G, Karkavelas G, Kalogera-Fountzila A, Karina M, Ignatiadis M, Koukoulis G, Plataniotis G, Misailidou D, Bobos M, Pectasides D, Razis E, Karavelis A, Selviaridis P: Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res; 2006 Nov-Dec;26(6C):4675-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.
  • BACKGROUND: Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT).
  • Two out of the five biomarkers studied, epidermal growth factor receptor (EGFR) and vascular endothelial growth factor-C (VEGF-C), were found to be overexpressed in 74% of the tumors, however they had no predictive value for progression-free or overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / metabolism. Astrocytoma / therapy. Biomarkers, Tumor / biosynthesis. Brain Neoplasms / metabolism. Brain Neoplasms / therapy. Glioblastoma / metabolism. Glioblastoma / therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Combined Modality Therapy. Cyclooxygenase 2 / biosynthesis. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Feasibility Studies. Female. Humans. Ki-67 Antigen / biosynthesis. Male. Middle Aged. PTEN Phosphohydrolase / biosynthesis. Patient Compliance. Postoperative Care. Vascular Endothelial Growth Factor C / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214326.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor C; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


40. Giannopoulou E, Ravazoula P, Kalofonos H, Makatsoris T, Kardamakis D: Expression of HIF-1alpha and iNOS in astrocytic gliomas: a clinicopathological study. In Vivo; 2006 May-Jun;20(3):421-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HIF-1alpha and iNOS in astrocytic gliomas: a clinicopathological study.
  • BACKGROUND: Hypoxia-inducible-factor-1 (HIF-1) is present at high levels in human tumors and plays a crucial role in tumor promotion by up-regulating several target genes.
  • PATIENTS AND METHODS: Sixty-three human astrocytic gliomas were analyzed by immunohistochemistry for HIF-1alpha and iNOS using formalin-fixed paraffin-embedded material.
  • RESULTS: HIF-1alpha was detected only in astrocytic gliomas grades III and IV, both in the nucleus and in the cytoplasm.
  • The iNOS expression was increased in astrocytic gliomas grades I, II and III and was statistically significantly decreased in astrocytic gliomas grade IV. iNOS was localized round the capillary vessels as well.
  • CONCLUSION: We believe that HIF-1alpha and iNOS expressions merit further investigations in order to understand the biology of astrocytic gliomas.
  • [MeSH-major] Astrocytoma / enzymology. Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Nitric Oxide Synthase Type II / biosynthesis
  • [MeSH-minor] Adult. Aged. Enzyme Induction. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724682.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


41. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H: L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer; 2006 Aug 1;119(3):484-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors.
  • We have investigated for the first time, the expression of the transporter in the human primary astrocytic tumor tissue from 60 patients.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Large Neutral Amino Acid-Transporter 1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acids, Cyclic / pharmacology. Animals. Antigens, CD98 Heavy Chain / analysis. Cell Line, Tumor. Cell Survival / drug effects. Child. Female. Glioma / drug therapy. Glioma / mortality. Glioma / pathology. Humans. Immunohistochemistry. Infant, Newborn. Male. Middle Aged. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / mortality. Neoplasms, Experimental / pathology. Rats. Rats, Wistar. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16496379.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Cyclic; 0 / Antigens, CD98 Heavy Chain; 0 / Large Neutral Amino Acid-Transporter 1; 20448-79-7 / 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid
  •  go-up   go-down


42. Katoh N, Shirato H, Aoyama H, Onimaru R, Suzuki K, Hida K, Miyasaka K, Iwasaki Y: Hypofractionated radiotherapy boost for dose escalation as a treatment option for high-grade spinal cord astrocytic tumor. J Neurooncol; 2006 May;78(1):63-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated radiotherapy boost for dose escalation as a treatment option for high-grade spinal cord astrocytic tumor.
  • PURPOSE: To retrospectively analyze the outcome of post-operative radiotherapy for spinal cord glioma with the emphasis on the hypofractionated radiotherapy boost for dose escalation as a treatment option for high-grade spinal cord astrocytic tumors.
  • There were 12 low-grade astrocytic tumors, 11 high-grade astrocytic tumors, 16 low-grade ependymal tumors and 2 high-grade ependymal tumors.
  • Among 11 patients with high-grade astrocytic tumors, 5 with anaplastic astrocytoma and 1 with glioblastoma received hypofractionated radiotherapy boost for dose escalation.
  • RESULTS: The Kaplan-Meier survival rates at 10 years from the date of the first surgery were 64% for the entire group, 47% for the astrocytic tumors and 84% for the ependymal tumors, respectively (P=0.009).
  • Among 11 patients with high-grade astrocytic tumors, the actuarial survival rate at 10 years was 35%.
  • DISCUSSION: The results for ependymal tumors and low-grade astrocytic tumors were comparable to those reported in the literature.
  • Hypofractionated radiotherapy boost for dose escalation may help to prolong the survival of patients with high-grade astrocytic tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314938.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


43. Li H, Wang Q, Gao F, Zhu F, Wang X, Zhou C, Liu C, Chen Y, Ma C, Sun W, Zhang L: Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas. Oncol Rep; 2008 Sep;20(3):573-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas.
  • Recently, a decreased expression of PDCD5 has been found in several types of human tumors.
  • We found that 53.3% (16/30) of the glioma samples had a reduced expression of PDCD5 mRNA and 70.5% (62/88) had a reduced expression of the PDCD5 protein as compared to normal brain tissue.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Blotting, Western. Female. Humans. Immunoenzyme Techniques. Male. Neoplasm Staging. Prognosis. RNA, Messenger. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695908.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins; 0 / PDCD5 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


44. Fathi AR, Vassella E, Arnold M, Curschmann J, Reinert M, Vajtai I, Weis J, Deiana G, Mariani L: Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status. Strahlenther Onkol; 2007 Sep;183(9):517-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status.
  • However, little is known about tumor response and its potential impact on long-term survival.
  • The volumetric tumor response after RT was assessed based on magnetic resonance imaging and graded according to standard criteria as complete, partial (PR, >or= 50%), or minor (MR, 25% to <50%).
  • The vast majority of the tumors had no loss of heterozygosity (LOH) 1p and/or 19q (86%).
  • CONCLUSION: Approximately 50% of patients with astrocytic WHO grade II gliomas respond to RT despite the absence of LOH for 1p/19q.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Microsatellite Repeats. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762927.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Korkolopoulou P, Perdiki M, Thymara I, Boviatsis E, Agrogiannis G, Kotsiakis X, Angelidakis D, Rologis D, Diamantopoulou K, Thomas-Tsagli E, Kaklamanis L, Gatter K, Patsouris E: Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol; 2007 Apr;38(4):629-38

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX.
  • It has been recently postulated that the hypoxia-inducible factor (HIF-1) pathway up-regulated by hypoxia accounts for CAIX overexpression in most human tumors.
  • In the present study, we examined the expression of this enzyme in diffuse gliomas of astrocytic origin in relation to vascular endothelial growth factor (VEGF) and HIF-1alpha expression, proliferation rate (as assessed with Ki-67 antigen), microvessel morphology, and survival.
  • Given the role of CAIX in the acidification of tumor environment and its up-regulation by hypoxia, it is thought that CAIX expression may be linked to resistance of tumor cells to radiotherapy by allowing them to acclimatize to a hypoxic and acidic microenvironment.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Astrocytoma / metabolism. Astrocytoma / pathology. Carbonic Anhydrases / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Survival Analysis. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367605.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Ki-67 Antigen; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


46. Andreiuolo F, Junier MP, Hol EM, Miquel C, Chimelli L, Leonard N, Chneiweiss H, Daumas-Duport C, Varlet P: GFAPdelta immunostaining improves visualization of normal and pathologic astrocytic heterogeneity. Neuropathology; 2009 Feb;29(1):31-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GFAPdelta immunostaining improves visualization of normal and pathologic astrocytic heterogeneity.
  • Neuropathological analysis of cellular mechanisms underlying gliosis and brain tumors is slowed by the lack of markers allowing to distinguish glial subpopulations in normal or pathological human brains.
  • Altogether these results show that combined GFAP, GFAPdelta and vimentin labelling reveals fine gliofilament regulation in normal and pathological brain.
  • [MeSH-major] Astrocytes / cytology. Astrocytes / pathology. Brain Diseases / pathology. Brain Neoplasms / pathology. Glial Fibrillary Acidic Protein / analysis. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / cytology. Brain / pathology. Brain Chemistry. Epilepsy / metabolism. Epilepsy / pathology. Female. Gliosis / metabolism. Gliosis / pathology. Hippocampus / chemistry. Hippocampus / pathology. Humans. Immunohistochemistry / methods. Male. Microscopy, Confocal. Middle Aged. Sclerosis / metabolism. Sclerosis / pathology. Vimentin / analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564099.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin
  •  go-up   go-down


47. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L: Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res; 2007 Mar 16;1137(1):161-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors.
  • The efficacy of cannabinoids against high-grade glioma in animal models, mediated by two specific receptors, CB1 and CB2, raised promises for targeted treatment of the most frequent and malignant primary brain tumors.
  • Unlike the abundantly expressed CB1, the CB2 receptor shows a restricted distribution in normal brain.
  • Although brain tumors constitute the second most common malignancy in children and the prevalence of histological types of brain tumors vary significantly between the adult and pediatric populations, cannabinoid receptor expression in pediatric tumors remains unknown.
  • In the present study, we compared the expression of the CB2 receptor in paraffin-embedded sections from primary brain tumors of adult and pediatric patients.
  • Most glioblastomas expressed very high levels of CB2 receptors and the expression correlated with tumor grade.
  • Interestingly, some benign pediatric astrocytic tumors, such as subependymal giant cell astrocytoma (SEGA), which may occasionally cause mortality owing to progressive growth, also displayed high CB2 immunoreactivity.
  • The high levels of CB2 expression would predestine those tumors to be vulnerable to cannabinoid treatment.
  • In contrast, all examined cases of embryonal tumors (medulloblastoma and S-PNET), the most frequently diagnosed malignant brain tumors in childhood, showed no or trace CB2 immunoreactivity.
  • Our results suggest that the CB2 receptor expression depends primarily on the histopathological origin of the brain tumor cells and differentiation state, reflecting the tumor grade.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Receptor, Cannabinoid, CB2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Astrocytoma / metabolism. Child. Glioblastoma / metabolism. Histocompatibility Antigens / metabolism. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239827.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 0 / Receptor, Cannabinoid, CB2
  •  go-up   go-down


48. Mikami S, Hirose Y, Yoshida K, Kawase T, Ohnishi A, Nagashima K, Mukai M, Okada Y, Ikeda E: Predominant expression of OLIG2 over ID2 in oligodendroglial tumors. Virchows Arch; 2007 May;450(5):575-84
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
  • This study aims to examine if the analysis of OLIG2 and ID2 expression in glioma tissues helps the differential diagnosis of chemosensitive oligodendroglial tumors from astrocytic tumors.
  • Expression levels of OLIG2 and ID2 in 11 oligodendroglial and 27 astrocytic tumors were analyzed by reverse transcription-polymerase chain reaction (RT-PCR), real-time quantitative PCR, and immunohistochemistry.
  • The mean expression level of OLIG2 was higher in oligodendroglial tumors than astrocytic tumors, but some astrocytic tumors showed high OLIG2 expression, indicating that OLIG2 cannot be an independent marker of oligodendroglial tumors.
  • No significant difference was observed between ID2 expression in oligodendroglial tumors and astrocytic tumors.
  • It was notable that OLIG2 expression was predominant over ID2 expression in oligodendroglial tumors, while ID2 expression was predominant over OLIG2 expression in astrocytic tumors.
  • These results indicate that the immunohistochemical study on the relative expression level of OLIG2 to ID2 can be a useful screening for oligodendroglial tumors.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Brain Neoplasms / metabolism. Inhibitor of Differentiation Protein 2 / metabolism. Nerve Tissue Proteins / metabolism. Oligodendroglia / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / metabolism. Astrocytoma / secondary. Astrocytoma / surgery. Biomarkers, Tumor / metabolism. Child. Chromosome Deletion. Chromosomes, Human, Pair 1. Female. Fluorescent Antibody Technique, Direct. Gene Expression. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Nucleic Acid Hybridization. Oligodendroglioma / metabolism. Oligodendroglioma / secondary. Oligodendroglioma / surgery. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431671.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / ID2 protein, human; 0 / Inhibitor of Differentiation Protein 2; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


49. Benedetti E, Galzio R, D'Angelo B, Cerù MP, Cimini A: PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. PPAR Res; 2010;2010:427401

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors.
  • Neuroepithelial tumors represent a heterogeneous class of human tumors including benignant and malignant tumors.
  • Among malignant neuroepithelial tumors, with regard to PPAR ligands, the most extensively studied were tumors of astrocytic origin and neuroblastoma.
  • PPARs are expressed in developing and adult neuroepithelial cells, even if with different localization and relative abundance.
  • The majority of malignant neuroepithelial tumors have poor prognosis and do not respond to conventional therapeutic protocols, therefore, new therapeutic approaches are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1129-38 [10706135.001]
  • [Cites] Mutat Res. 2000 Mar 17;448(2):121-38 [10725467.001]
  • [Cites] Biochim Biophys Acta. 2000 May 1;1474(3):397-409 [10779693.001]
  • [Cites] J Neurosci Res. 2000 Jul 1;61(1):67-74 [10861801.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5119-28 [10866668.001]
  • [Cites] Neoplasia. 1999 Oct;1(4):330-9 [10935488.001]
  • [Cites] J Neurosci. 2000 Sep 15;20(18):6862-7 [10995830.001]
  • [Cites] EXS. 2000;89:141-51 [10997287.001]
  • [Cites] Int J Dev Biol. 2000 Aug;44(5):429-42 [11032176.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5558-64 [11034103.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Neuropathology. 2000 Sep;20(3):161-9 [11132930.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):98-104 [11205925.001]
  • [Cites] Glia. 2001 Mar 1;33(3):191-204 [11241737.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):160-6 [11307058.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):37-41 [11464901.001]
  • [Cites] Neurochem Res. 2006 Nov;31(11):1305-16 [17053972.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1134-7 [17184491.001]
  • [Cites] Neurosci Lett. 2007 Apr 24;417(1):72-7 [17324516.001]
  • [Cites] J Cell Physiol. 2007 Jun;211(3):837-47 [17390299.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1745-54 [17541035.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1771(8):1031-45 [17569578.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(11):2093-106 [17662640.001]
  • [Cites] J Cell Physiol. 2008 Oct;217(1):93-102 [18446822.001]
  • [Cites] Stem Cell Rev. 2008 Dec;4(4):293-303 [18561036.001]
  • [Cites] Acta Pharmacol Sin. 2009 Jul;30(7):935-46 [19503102.001]
  • [Cites] Endocrinology. 2001 Oct;142(10):4195-202 [11564675.001]
  • [Cites] J Neurocytol. 2001 Jan;30(1):21-33 [11577243.001]
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1747-55 [11698335.001]
  • [Cites] Bull Cancer. 2002 Jan;89(1):23-8 [11847022.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2613-8 [11867749.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Int J Dev Biol. 2002 Jan;46(1):105-14 [11902671.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):1052-60 [12065618.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(14):5114-27 [12077340.001]
  • [Cites] J Neurocytol. 2001 Aug;30(8):671-83 [12118155.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1141-50 [12370766.001]
  • [Cites] J Chem Neuroanat. 2003 Jan;25(1):29-38 [12573457.001]
  • [Cites] Curr Opin Lipidol. 2003 Apr;14(2):129-35 [12642780.001]
  • [Cites] Front Biosci. 2003 May 1;8:d577-88 [12700119.001]
  • [Cites] Brain Res. 2003 Jun 13;975(1-2):10-21 [12763589.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] J Neurochem. 2003 Nov;87(3):742-51 [14535956.001]
  • [Cites] Neuroscience. 2004;123(1):131-45 [14667448.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):8976-85 [14699130.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23882-91 [15051725.001]
  • [Cites] Biochem J. 2004 Aug 15;382(Pt 1):83-91 [15171682.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):419-29 [15231248.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):493-502 [15254749.001]
  • [Cites] Oncol Res. 2004;14(7-8):345-54 [15301425.001]
  • [Cites] Biochem Soc Trans. 2004 Nov;32(Pt 5):840-2 [15494029.001]
  • [Cites] Neuroscience. 2005;130(2):325-37 [15664689.001]
  • [Cites] J Pharmacol Exp Ther. 2005 May;313(2):806-13 [15665144.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):14145-53 [15695504.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2340-5 [15701701.001]
  • [Cites] Neuroscience. 2005;131(3):577-87 [15730864.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18667-82 [15774422.001]
  • [Cites] Neoplasma. 2005;52(2):126-36 [15800711.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2684-94 [15829979.001]
  • [Cites] Toxicology. 2005 Sep 15;213(1-2):157-68 [16009482.001]
  • [Cites] Prog Lipid Res. 2006 Mar;45(2):120-59 [16476485.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] Apoptosis. 2006 Sep;11(9):1503-12 [16820965.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1524-33 [16887936.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Sep;15(9):1039-49 [16916271.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):879-88 [16969347.001]
  • [Cites] Cell. 1992 Mar 6;68(5):879-87 [1312391.001]
  • [Cites] J Cell Physiol. 1992 Sep;152(3):536-44 [1506412.001]
  • [Cites] Nature. 1990 Oct 18;347(6294):645-50 [2129546.001]
  • [Cites] N Engl J Med. 1985 Oct 31;313(18):1111-6 [4047115.001]
  • [Cites] Cancer Res. 1973 Nov;33(11):2643-52 [4748425.001]
  • [Cites] Science. 1984 Jun 8;224(4653):1121-4 [6719137.001]
  • [Cites] J Natl Cancer Inst. 1982 Apr;68(4):589-96 [7040765.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):354-66 [8536636.001]
  • [Cites] Cell Growth Differ. 1996 Jun;7(6):775-85 [8780891.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41 [8990192.001]
  • [Cites] J Neurosci Res. 1998 Mar 1;51(5):563-73 [9512000.001]
  • [Cites] J Neurochem. 1998 Apr;70(4):1366-75 [9523552.001]
  • [Cites] Endocrinology. 1998 Jun;139(6):2748-54 [9607781.001]
  • [Cites] Mol Cell. 1998 Feb;1(3):465-70 [9660931.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3344-52 [9699665.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):137-43 [9744270.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1049-55 [9797355.001]
  • [Cites] J Nutr. 1999 Feb;129(2S Suppl):575S-580S [10064336.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] J Biol Chem. 1999 Dec 10;274(50):35881-8 [10585473.001]
  • [Cites] Nature. 2000 Jan 6;403(6765):103-8 [10638762.001]
  • [Cites] J Med Chem. 2000 Feb 24;43(4):527-50 [10691680.001]
  • (PMID = 20339586.001).
  • [ISSN] 1687-4765
  • [Journal-full-title] PPAR research
  • [ISO-abbreviation] PPAR Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2841252
  •  go-up   go-down


50. Hlobilkova A, Ehrmann J, Sedlakova E, Krejci V, Knizetova P, Fiuraskova M, Kala M, Kalita O, Kolar Z: Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression? Neoplasma; 2007;54(4):334-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
  • The aim of our study was to detect changes in expression of the following proteins: the tumor suppressors PTEN, p53, and p21Waf1/Cip1, glial fibrillary acidic protein (GFAP, as a marker of astroglial differentiation), the phosphorylated form of protein kinase B/Akt (PKB/Akt), which is downstream to the epidermal growth factor receptor (EGFR), and MDM2, which degrades p53.
  • PTEN was not found in most of astrocytomas, 64% of low grade and 74% of high grade tumors showed no PTEN staining.
  • GFAP expression was decreased in tumor astrocytes compared to normal astrocytes and this decreased with grading.
  • GFAP positive tumor cells were detected in only 50% of low grade, and 32% of high grade astrocytomas.
  • Loss of p21Waf1/Cip1 expression was shown in 20% of low and in 45% of high grade tumors.
  • In the subgroup of high grade tumors with wild type p53, 86% showed p21Waf1/Cip1 expression, whereas in the subgroup of high grade tumors with altered p53, only 35% displayed p21Waf1/Cip1.
  • PTEN defects may also participate in aggressive tumor behaviour through activation of the PKB/Akt pathway.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Male. Middle Aged. Mutation / genetics. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. PTEN Phosphohydrolase / metabolism. Phosphorylation. Proto-Oncogene Proteins c-mdm2 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822324.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


51. Miwa T, Hirose Y, Sasaki H, Ikeda E, Yoshida K, Kawase T: Genetic characterization of adult infratentorial gliomas. J Neurooncol; 2009 Feb;91(3):251-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic characterization of adult infratentorial gliomas.
  • Adult infratentorial gliomas are rare and have not been well studied.
  • We therefore conducted genetic analysis of those tumors to see if there was any characteristic that could be relevant in clinical management and understanding of tumorigenesis.
  • Nineteen adult infratentorial gliomas were analyzed for chromosomal aberration by comparative genomic hybridization, and for expression of p53 and epidermal growth factor receptor (EGFR) by immunohistochemistry.
  • However, the gain of 7q, the characteristic abnormality of supratentorial astrocytomas commonly associated with the gaining of 7p, was observed only in 1 of 11 adult infratentorial astrocytic tumors.
  • Our findings might suggest the presence of distinct tumorigenic pathway in adult infratentorial gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Frontal Lobe / pathology. Glioma / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Chromosome Aberrations. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 7 / genetics. Comparative Genomic Hybridization. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941867.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


52. Gunal A, Onguru O, Safali M, Beyzadeoglu M: Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas. Neuropathology; 2008 Aug;28(4):382-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas.
  • In this study, we evaluated fascin expression in glial tumors and its relation with histologic grade.
  • Seventy-six glial tumors including 44 glioblastomas with known survival time, 18 anaplastic astrocytomas (AAs), six diffuse astrocytomas (DAs), and eight pilocytic astrocytomas (PAs) were examined immunohistochemically for fascin expression.
  • Fascin was observed in the neurons of normal brain tissue and endothelium of vascular spaces in the glial tumors.
  • In conclusion, fascin expression levels are correlated with histologic grade and fascin overexpression may play an important role in the biologic behavior of glial astrocytic tumors and in the prognosis of GBs.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / biosynthesis. Glioblastoma / metabolism. Microfilament Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Astrocytoma / metabolism. Astrocytoma / mortality. Astrocytoma / pathology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298442.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


53. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol; 2009 Oct;118(4):469-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
  • IDH2 encoding mitochondrial NADP+-dependent isocitrate dehydrogenase is also mutated in these tumors, albeit at much lower frequencies.
  • Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors.
  • We report on an inverse association of IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the tumor entities.
  • IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Isocitrate Dehydrogenase / genetics
  • [MeSH-minor] Adult. Age Factors. Brain / pathology. Cell Differentiation. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Mutation. Prognosis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554337.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


54. Tanaka A: Imaging diagnosis and fundamental knowledge of common brain tumors in adults. Radiat Med; 2006 Jul;24(6):482-92
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging diagnosis and fundamental knowledge of common brain tumors in adults.
  • The most common primary brain tumors in Japanese adults are meningiomas, gliomas, pituitary adenomas, and schwannomas, which together account for 84.0% of all primary brain tumors.
  • The typical imaging findings of these tumors are well known by radiologists; therefore, the clinical and pathological issues, including terminology, genetics, and relation to hormones are discussed in this article.
  • The molecular genetic analysis of brain tumors has recently become important.
  • For instance, genetic analysis is important for differentiating oligodendroglial tumors from astrocytic tumors, and the gene mutation predicts response to chemotherapy for anaplastic oligodendrogliomas.
  • Background factors such as hormones, history of cranial irradiation, and medications influence oncogenesis, tumor growth, and tumor appearances as seen by imaging modalities.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Glioma / diagnosis. Humans. Image Processing, Computer-Assisted. Japan / epidemiology. Meningioma / diagnosis. Neurilemmoma / diagnosis. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16958433.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 31
  •  go-up   go-down


55. Takeuchi H, Kubota T, Kitai R, Matsuda K, Hashimoto N, Sato K: Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component. J Neurooncol; 2009 Jan;91(1):33-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component.
  • Malignant glioneuronal tumors (MGNT) are suggested to be a new entity of glioma defined morphologically as any malignant glioma showing immunohistoichemical evidence of neuronal differentiation.
  • We encountered seven cases of MGNT with oligodendroglioma-like component and investigated alternations of chromosome 1p and 19q in these tumors.
  • Immunohistochemical study of these tumors was performed using neuronal markers (synaptophysin, neurofilament, beta-tubulin, chromogranin A and NeuN), astrocytic marker (GFAP) and Ki-67.
  • We undertook a molecular cytogenetic study of tumor specimens obtained from seven patients using fluorescence in situ hybridization (FISH) with DNA probes mapping to chromosome 1p36, 1q25, 19p13 and 19q13.
  • Histologically, these tumors resembled anaplastic oligodendroglioma.
  • Immunohistochemically, tumor cells were immunoreactive for synaptophysin (7/7), neurofilament (6/7), beta-tubulin (5/7), chromogranin A (4/7), NeuN (2/7) and GFAP (7/7).
  • We suggest that the oligodendroglial-like feature was associated with not only 1p or 19q loss but also differentiation along neuronal cell lines as a factor of favorable prognosis in glial tumors.
  • [MeSH-major] Brain Neoplasms / metabolism. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Oligodendroglia / metabolism. Oligodendroglia / pathology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18781279.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins
  •  go-up   go-down


56. Sawada T, Kato Y, Kobayashi M: Expression of aquaporine-4 in central nervous system tumors. Brain Tumor Pathol; 2007;24(2):81-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aquaporine-4 in central nervous system tumors.
  • Cerebral edema is associated with common brain tumors.
  • To elucidate the characterization of the expression of AQP4 and the relationship of the expression of VEGF, we investigated the expression of AQP4 in tumors of the central nervous system immunohistochemically.
  • Brain tumors and nontumorous cerebral tissue for control were evaluated by immunohistochemical staining using anti-AQP4, VEGF, CD34, and MIB-1.
  • In tumor cells, only glial tumor cells showed a positive reaction for AQP4.
  • Although endothelial cells were negative and/or weakly positive for AQP4, the positive relationship suggested the expression of VEGF in endothelial cells in neovasculature and that of AQP 4 in tumor cells.
  • APQ4 expression increased in human astrocytic tumors and edematous cerebral tissue.
  • Upregulation of APQ4 by tumor cells and reactive astroglia were major factors of cerebral edema.
  • [MeSH-major] Aquaporin 4 / biosynthesis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Astrocytes / metabolism. Brain Edema / etiology. Brain Edema / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Up-Regulation. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095136.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


57. Motta FJ, Valera ET, Lucio-Eterovic AK, Queiroz RG, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG, Marie SK, Tone LG: Differential expression of E-cadherin gene in human neuroepithelial tumors. Genet Mol Res; 2008;7(2):295-304
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of E-cadherin gene in human neuroepithelial tumors.
  • This study aimed to evaluate the expression of E-cadherin and their correlation with clinical features in microdissected brain tumor samples from 81 patients, divided into 62 astrocytic tumors grades I to IV and 19 medulloblastomas, and from 5 white matter non-neoplasic brain tissue samples.
  • We observed a decrease in expression among pathological grades of neuroepithelial tumors.
  • Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than did neuroepithelial tumors.
  • Expression of E-cadherin gene was higher in astrocytic than embryonal tumors (P = 0.0168).
  • Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than grade I malignancy astrocytomas, considered as benign tumors (P = 0.0473).
  • These results suggest that a decrease in E-cadherin gene expression level in high-grade neuroepithelial tumors may be a hallmark of malignancy in dedifferentiated tumors and that it may be possibly correlated with their progression and dissemination.
  • [MeSH-minor] Adolescent. Adult. Brain / metabolism. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551395.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  •  go-up   go-down


58. Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger AB: Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res; 2007 Jun 15;13(12):3559-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.
  • EXPERIMENTAL DESIGN: We studied the frequency and extent of CYP1B1 expression by immunohistochemical analysis in 269 glial tumors (including all major pathologic types) on a tissue microarray.
  • RESULTS: Overall, increased CYP1B1 expression in glial tumors was associated with decreased patient survival time (P < 0.0014 for both percentage and intensity of staining).
  • A significant difference existed in percentage and intensity of staining between astrocytic and oligodendroglial tumors (P = 0.0002 and 0.0003, respectively), between grades of tumors (P < 0.0001 and 0.0079), and between pathologic types of tumors (P < 0.0001 and 0.0339).
  • Paradoxically, within specific tumor pathologies, there was a trend toward increased survival as CYP1B1 expression increased.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cytochrome P-450 Enzyme System / biosynthesis. Gene Expression. Glioma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Aryl Hydrocarbon Hydroxylases. Child. Child, Preschool. Cytochrome P-450 CYP1B1. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575219.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1B1
  •  go-up   go-down


59. Jacobs JF, Grauer OM, Brasseur F, Hoogerbrugge PM, Wesseling P, Gidding CE, van de Rakt MW, Figdor CG, Coulie PG, de Vries IJ, Adema GJ: Selective cancer-germline gene expression in pediatric brain tumors. J Neurooncol; 2008 Jul;88(3):273-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective cancer-germline gene expression in pediatric brain tumors.
  • Cancer-germline genes (CGGs) code for immunogenic antigens that are present in various human tumors and can be targeted by immunotherapy.
  • Their expression has been studied in a wide range of human tumors in adults.
  • We measured the expression of 12 CGGs in pediatric brain tumors, to identify targets for therapeutic cancer vaccines.
  • Real Time PCR was used to quantify the expression of genes MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MAGE-C2, NY-ESO-1 and GAGE-1,2,8 in 50 pediatric brain tumors of different histological subtypes.
  • Fifty-five percent of the medulloblastomas (n = 11), 86% of the ependymomas (n = 7), 40% of the choroid plexus tumors (n = 5) and 67% of astrocytic tumors (n = 27) expressed one or more CGGs.
  • With exception of a minority of tumors, the overall level of CGG expression in pediatric brain tumors was low.
  • CGG-encoded antigens are therefore suitable targets in a very selected group of pediatric patients with a brain tumor.
  • Interestingly, glioblastomas from adult patients expressed CGGs more often and at significantly higher levels compared to pediatric glioblastomas.
  • This observation is in line with the notion that pediatric and adult glioblastomas develop along different genetic pathways.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression. Genes, Neoplasm
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Humans. Immunohistochemistry. Infant. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] In Vivo. 2002 Nov-Dec;16(6):583-8 [12494904.001]
  • [Cites] Immunol Rev. 2002 Oct;188:51-64 [12445281.001]
  • [Cites] Nat Rev Immunol. 2003 Jul;3(7):569-81 [12876559.001]
  • [Cites] Clin Neuropathol. 2003 Jul-Aug;22(4):180-6 [12908754.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):3-11 [12952281.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):777-84 [17957795.001]
  • [Cites] Int Rev Immunol. 2003 Mar-Apr;22(2):113-40 [12962272.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):527-8 [8509230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1004-8 [8302824.001]
  • [Cites] Annu Rev Immunol. 1994;12:337-65 [8011285.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):967-72; discussion 972-3 [8084407.001]
  • [Cites] N Engl J Med. 1995 Jan 19;332(3):143-9 [7800006.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2236-9 [7757970.001]
  • [Cites] Mod Pathol. 1995 Apr;8(3):333-8 [7617661.001]
  • [Cites] Ther Immunol. 1995 Jun;2(3):173-81 [8885135.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):782-9 [9210874.001]
  • [Cites] Biotechniques. 1997 Sep;23(3):456-60 [9298216.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Neurol Res. 2005 Oct;27(7):692-702 [16197806.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):67-74 [17019710.001]
  • [Cites] Cancer Immunol Immunother. 2007 Feb;56(2):259-69 [16758204.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000 [17143233.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Exp Med. 2007 Sep 3;204(9):2023-30 [17682068.001]
  • [Cites] Int J Oncol. 2000 Jan;16(1):81-96 [10601552.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):835-41 [10842198.001]
  • [Cites] Transplantation. 2000 Jun 15;69(11):2366-73 [10868642.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):856-60 [11351307.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] Clin Chem. 2002 Jan;48(1):25-34 [11751535.001]
  • [Cites] Vaccine. 2003 Jan 30;21(7-8):781-6 [12531359.001]
  • (PMID = 18398575.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2440921
  •  go-up   go-down


60. Hirose T, Ishizawa K, Shimada S: Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors. Neuropathology; 2010 Dec;30(6):586-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
  • To improve the diagnostic accuracy of oligodendroglial tumors and to find more convenient parameters that could predict the cytogenetic status, oligodendroglial and astrocytic tumors were cytogenetically and immunohistochemically investigated.
  • Materials included 22 oligodendroglial tumors (15 oligodendrogliomas and 7 oligoastrocytomas) and 20 astrocytic tumors.
  • Furthermore, TP53 mutation analyses were carried out on three oligodendroglial tumors showing p53 protein overexpression with a direct sequence analysis.
  • Our FISH studies demonstrated 1p loss in 73% of oligodendroglial tumors (80% oligodendrogliomas and 57% oligoastrocytomas) and in only 10% of astrocytic tumors.
  • There were no clear-cut morphologic differences between 1p-deleted and 1p-intact oligodendroglial tumors.
  • GFAP and Olig2 were expressed in most oligodendroglial and astrocytic tumors, and their cellular localization was almost independent of each other.
  • Overexpression of p53 was observed in five oligodendroglial tumors, all of which were 1p-intact.
  • In comparison, 16 oligodendroglial tumors with 1p deletion showed no overexpression of p53.
  • TP53 missense mutations were detected in three of the p53 overexpressed oligodendroglial tumors studied.
  • Our results suggest that 1p loss is almost specific to oligodendroglial tumors.
  • Although the prediction of 1p status based solely on the morphologic features seems to be difficult, the immunohistochemistry for p53 is a useful tool in that p53 overexpression is closely related to the 1p-intact status in oligodendroglial tumors.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Chromosomes, Human, Pair 1 / genetics. Oligodendroglioma / diagnosis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Female. Gene Deletion. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Nerve Tissue Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Society of Neuropathology.
  • (PMID = 20408960.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glial Fibrillary Acidic Protein; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


61. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol; 2008 Dec;116(6):597-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the IDH1 codon 132 mutation in brain tumors.
  • We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
  • The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development.
  • [MeSH-major] Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18985363.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


62. Juhász C, Chugani DC, Muzik O, Wu D, Sloan AE, Barger G, Watson C, Shah AK, Sood S, Ergun EL, Mangner TJ, Chakraborty PK, Kupsky WJ, Chugani HT: In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors. J Cereb Blood Flow Metab; 2006 Mar;26(3):345-57
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors.
  • Abnormal metabolism of tryptophan has been implicated in modulation of tumor cell proliferation and immunoresistance. alpha-[(11)C]Methyl-L-tryptophan (AMT) is a PET tracer to measure cerebral tryptophan metabolism in vivo.
  • In the present study, we have measured tumor tryptophan uptake in 40 patients with primary brain tumors using AMT PET and standard uptake values (SUV).
  • All grade II to IV gliomas and glioneuronal tumors showed increased AMT SUV, including all recurrent/residual tumors.
  • Gadolinium enhancement on MRI was associated with high VD' values, suggesting impaired blood-brain barrier, while k(3)' values were not related to contrast enhancement.
  • Low-grade astrocytic gliomas showed increased tryptophan metabolism, as measured by k(3)'.
  • In astrocytic tumors, low grade was associated with high k(3)' and lower VD', while high-grade tumors showed the reverse pattern.
  • The findings show high AMT uptake in primary and residual/recurrent gliomas and glioneuronal tumors.
  • Increased AMT uptake can be due to increased metabolism of tryptophan and/or high volume of distribution, depending on tumor type and grade.
  • High tryptophan metabolic rates in low-grade tumors may indicate activation of the kynurenine pathway, a mechanism regulating tumor cell growth.
  • AMT PET might be a useful molecular imaging method to guide therapeutic approaches aimed at controlling tumor cell proliferation by acting on tryptophan metabolism.
  • [MeSH-major] Brain Neoplasms / metabolism. Cerebral Cortex / metabolism. Tryptophan / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon Radioisotopes. Child. Child, Preschool. Electroencephalography / methods. Electroencephalography / standards. Female. Gadolinium. Glucose / metabolism. Humans. Infant. Magnetic Resonance Imaging / methods. Magnetic Resonance Imaging / standards. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Positron-Emission Tomography / standards. Seizures / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16079785.001).
  • [ISSN] 0271-678X
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 13510-08-2 / alpha-methyltryptophan; 8DUH1N11BX / Tryptophan; AU0V1LM3JT / Gadolinium; IY9XDZ35W2 / Glucose
  •  go-up   go-down


63. Hänninen MM, Haapasalo J, Haapasalo H, Fleming RE, Britton RS, Bacon BR, Parkkila S: Expression of iron-related genes in human brain and brain tumors. BMC Neurosci; 2009;10:36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of iron-related genes in human brain and brain tumors.
  • Although the expression of genes involved in normal iron balance has been intensively studied in other tissues, little is known about their expression in the brain.
  • We investigated the mRNA levels of hepcidin (HAMP), HFE, neogenin (NEO1), transferrin receptor 1 (TFRC), transferrin receptor 2 (TFR2), and hemojuvelin (HFE2) in normal human brain, brain tumors, and astrocytoma cell lines.
  • The specimens included 5 normal brain tissue samples, 4 meningiomas, one medulloblastoma, 3 oligodendrocytic gliomas, 2 oligoastrocytic gliomas, 8 astrocytic gliomas, and 3 astrocytoma cell lines.
  • In most tumor types, the pattern of gene expression was diverse.
  • Notable findings include high expression of transferrin receptor 1 in the hippocampus and medulla oblongata compared to other brain regions, low expression of HFE in normal brain with elevated HFE expression in meningiomas, and absence of hepcidin mRNA in astrocytoma cell lines despite expression in normal brain and tumor specimens.
  • CONCLUSION: These results indicate that several iron-related genes are expressed in normal brain, and that their expression may be dysregulated in brain tumors.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Histocompatibility Antigens Class I / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / genetics. Antigens, CD / metabolism. Antimicrobial Cationic Peptides / genetics. Antimicrobial Cationic Peptides / metabolism. Astrocytoma / genetics. Astrocytoma / metabolism. Cell Line, Tumor. Female. GPI-Linked Proteins. Hepcidins. Humans. Male. Meningioma / genetics. Meningioma / metabolism. Middle Aged. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. RNA, Messenger / analysis. Receptors, Transferrin / genetics. Receptors, Transferrin / metabolism. Statistics, Nonparametric. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histochem Cell Biol. 2001 Mar;115(3):195-203 [11326747.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G590-4 [16537971.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2213-21 [11489794.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1337-43 [11535709.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):1037-44 [12370282.001]
  • [Cites] Biometals. 2003 Mar;16(1):63-75 [12572665.001]
  • [Cites] Blood. 2003 Aug 1;102(3):783-8 [12663437.001]
  • [Cites] Brain Res Bull. 2003 Aug 30;61(4):365-74 [12909279.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 May;5(5):343-54 [15122348.001]
  • [Cites] Nat Rev Neurosci. 2004 Nov;5(11):863-73 [15496864.001]
  • [Cites] J Neurosurg. 1990 Jun;72(6):941-5 [2159987.001]
  • [Cites] Nat Genet. 1996 Aug;13(4):399-408 [8696333.001]
  • [Cites] J Comp Neurol. 1996 Nov 25;375(4):675-92 [8930792.001]
  • [Cites] J Neurol Sci. 2004 Dec 15;227(1):27-33 [15546588.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2090-3 [15514116.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dev Comp Immunol. 2005;29(11):939-50 [15935472.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):33885-94 [16103117.001]
  • [Cites] BMC Neurol. 2006;6:24 [16824219.001]
  • [Cites] J Neurosci Res. 2006 Sep;84(4):790-800 [16933319.001]
  • [Cites] J Alzheimers Dis. 2006 Nov;10(2-3):215-22 [17119289.001]
  • [Cites] J Alzheimers Dis. 2006 Nov;10(2-3):267-76 [17119292.001]
  • [Cites] J Histochem Cytochem. 2007 Jan;55(1):85-96 [16982849.001]
  • [Cites] Eur J Haematol. 2007 Jan;78(1):1-10 [17042775.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1926-32 [17557118.001]
  • [Cites] Retina. 2007 Oct;27(8):997-1003 [18040235.001]
  • [Cites] Blood. 2008 Jan 15;111(2):924-31 [17938254.001]
  • [Cites] Biochemistry. 2008 Apr 8;47(14):4237-45 [18335997.001]
  • [Cites] Cell Metab. 2008 Apr;7(4):288-90 [18396134.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17494-502 [18445598.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):967-75 [18987634.001]
  • [Cites] BMC Cancer. 2005;5:154 [16324219.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7806-10 [11113131.001]
  • (PMID = 19386095.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antimicrobial Cationic Peptides; 0 / CD71 antigen; 0 / GPI-Linked Proteins; 0 / HAMP protein, human; 0 / HFE protein, human; 0 / HFE2 protein, human; 0 / Hepcidins; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Transferrin; 0 / TFR2 protein, human; 0 / neogenin
  • [Other-IDs] NLM/ PMC2679039
  •  go-up   go-down


64. Yamasaki F, Kurisu K, Satoh K, Arita K, Sugiyama K, Ohtaki M, Takaba J, Tominaga A, Hanaya R, Yoshioka H, Hama S, Ito Y, Kajiwara Y, Yahara K, Saito T, Thohar MA: Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology; 2005 Jun;235(3):985-91
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent diffusion coefficient of human brain tumors at MR imaging.
  • PURPOSE: To determine if apparent diffusion coefficient (ADC) can be used to differentiate brain tumors at magnetic resonance (MR) imaging.
  • MR images were reviewed retrospectively in 275 patients with brain tumors: 147 males and 128 females 1-81 years old, treated between September 1997 and July 2003.
  • Regions of interest were placed manually in tumor regions on MR images, and ADC was calculated with a five-point regression method at b values of 0, 250, 500, 750, and 1000 sec/mm2.
  • ADC values were average values in tumor.
  • All brain tumor subgroups were analyzed.
  • Logistic discriminant analysis was performed by using ADC, age, and patient sex as independent variables to discriminate among tumor groups.
  • RESULTS: A significant negative correlation existed between ADC and astrocytic tumors of World Health Organization grades 2-4 (grade 2 vs grades 3 and 4, accuracy of 91.3% [P < .01]; grade 3 vs 4, accuracy of 82.4% [P < .01]).
  • ADC of dysembryoplastic neuroepithelial tumors (DNTs) was higher than that of astrocytic grade 2 tumors (accuracy, 100%) and other glioneuronal tumors.
  • ADC of malignant lymphomas was lower than that of glioblastomas and metastatic tumors (accuracy, 83.6%; P < .01).
  • ADC of primitive neuroectodermal tumors (PNETs) was lower than that of ependymomas (accuracy, 100%).
  • ADC of epidermoid tumors was lower than that of chordomas (accuracy, 100%).
  • CONCLUSION: ADC is useful for differentiation of some human brain tumors, particularly DNT, malignant lymphomas versus glioblastomas and metastatic tumors, and ependymomas versus PNETs.
  • [MeSH-major] Brain Neoplasms / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2005.
  • (PMID = 15833979.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Eckert A, Kloor M, Giersch A, Ahmadi R, Herold-Mende C, Hampl JA, Heppner FL, Zoubaa S, Holinski-Feder E, Pietsch T, Wiestler OD, von Knebel Doeberitz M, Roth W, Gebert J: Microsatellite instability in pediatric and adult high-grade gliomas. Brain Pathol; 2007 Apr;17(2):146-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability in pediatric and adult high-grade gliomas.
  • About 15% of sporadic gastrointestinal and endometrial tumors show the microsatellite instability (MSI) phenotype because of loss of DNA mismatch repair (MMR) function.
  • The incidence of MSI in tumors of the central nervous system still remains controversial.
  • Based on these data and the fact that in different tumor entities MMR deficiency defines a subgroup of tumors with distinct pathogenesis and particular clinicopathological features that may have impact on prognosis and therapy, we screened 624 gliomas from 71 young and 553 adult patients for MMR deficiency by MSI analysis using three highly sensitive diagnostic markers.
  • A malignant glioma from an adult patient displayed MSI and concomitant loss of nuclear MSH2 and MSH6 protein expression (0.16%; 1/619).
  • No evidence for MSI or loss of MMR protein expression was observed in 71 gliomas from young patients (0%; 0/71) including 41 high-grade astrocytic tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Microsatellite Instability
  • [MeSH-minor] Adult. Child. DNA-Binding Proteins / metabolism. Humans. Immunohistochemistry. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388945.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA-Binding Proteins
  •  go-up   go-down


66. Rodriguez FJ, Scheithauer BW, Jenkins R, Burger PC, Rudzinskiy P, Vlodavsky E, Schooley A, Landolfi J: Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study. Am J Surg Pathol; 2007 Mar;31(3):351-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
  • Gliosarcomas are morphologically biphasic tumors composed of glial and sarcomatous elements.
  • Seven patients with oligodendroglial tumors and a sarcomatous component were identified.
  • At first resection, the tumors included grade II oligodendroglioma (n=3), grade III oligodendroglioma (n=1), grade II oligoastrocytoma (n=1), and grade III oligoastrocytoma (n=2).
  • The sarcomatous component developed in recurrent/progressive tumors in 6 cases but was a focal finding at first tumor resection in 1 and included fibrosarcoma (n=5), leiomyosarcoma (n=1), or pleomorphic myogenic sarcoma (n=1).
  • Rhabdoid change was a focal finding in the sarcomatous component of 1 tumor.
  • The relatively frequent presence of 1p/19q codeletion in both glial and sarcomatous components supports the notion that the sarcomatous component represents a metaplastic change occurring in the glial element, the same mechanism active in classic astrocytic gliosarcomas.
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasms, Second Primary / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Brain / surgery. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325476.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


67. Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C: Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol; 2010 Aug;120(2):261-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
  • The current WHO classification of brain tumors defines gliomatosis cerebri (GC) as an extensively infiltrating astrocytic glioma involving at least three cerebral lobes.
  • Recent reports showed IDH1 mutations in astrocytic and oligodendroglial tumors WHO grades II and III and in secondary glioblastomas with a frequency of up to 90%, whereas IDH1 mutations occurred in only 5% of primary glioblastomas.
  • We identified IDH1 mutations in 10/24 (42%) cases, which also included a solid tumor portion (type 2 GC), but not in 11 "classical" cases without solid tumor mass (type 1 GC).
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Isocitrate Dehydrogenase / genetics. Mutation / genetics. Neoplasms, Neuroepithelial / genetics. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Arginine / genetics. Astrocytoma / secondary. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Mutational Analysis. Female. Histidine / genetics. Humans. In Situ Hybridization, Fluorescence / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Oligodendroglioma / secondary. Polymorphism, Single Nucleotide / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


68. Bulakbasi N, Kocaoglu M, Farzaliyev A, Tayfun C, Ucoz T, Somuncu I: Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary malignant brain tumors. AJNR Am J Neuroradiol; 2005 Oct;26(9):2187-99
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary malignant brain tumors.
  • PURPOSE: The purpose of this study was to estimate the diagnostic accuracy of relative cerebral blood volume (rCBV) measurement in preoperative grading and differentiation of solitary intra-axial malignant brain tumors.
  • METHODS: Thirty-six low-grade glial tumors (LGGTs), 22 high-grade glial tumors (HGGTs), and 17 metastases (METs) were prospectively evaluated by MR imaging and standard dynamic susceptibility contrast-enhanced gradient echo, echoplanar imaging during first pass of a bolus injection of contrast material.
  • HGA) astrocytomas when nonastrocytic glial tumors were excluded.
  • CONCLUSION: The diagnostic accuracy of rCBV measurement is higher in grading of glial brain tumors than in differentiation of HGGTs from solitary intra-axial METs.
  • The astrocytic and nonastrocytic glial tumors have to be evaluated separately for precise grading.
  • [MeSH-major] Blood Volume. Brain Neoplasms / blood supply. Cerebrovascular Circulation. Magnetic Resonance Angiography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Contrast Media. Echo-Planar Imaging. Glioma / blood supply. Glioma / pathology. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219821.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


69. Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M: Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed; 2005 Oct;18(6):371-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation.
  • High-resolution proton magnetic resonance spectroscopy was performed on tissue specimens from 33 patients with astrocytic tumors (22 astrocytomas, 11 glioblastomas) and 13 patients with meningiomas.
  • For all patients, samples of primary tumors and their first recurrences were examined.
  • Spectroscopic features of tumor types, as determined on samples of the primary occurrences, were in good agreement with previous studies.
  • Metabolic changes of an evolving tumor were observed in recurrent astrocytomas: owing to their consecutive assessments, more indicators of malignant degeneration were detected in astrocytoma recurrences (e.g.
  • The present investigation demonstrated a correlation of the tCho-signal with tumor progression.
  • This may be related to an early stage of malignant transformation, not yet detectable morphologically, and emphasizes the high sensitivity of 1H NMR spectroscopy in elucidating characteristics of brain tumor metabolism.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Magnetic Resonance Spectroscopy / methods. Meningioma / metabolism. Neoplasm Recurrence, Local / metabolism
  • [MeSH-minor] Adult. Humans. Middle Aged. Protons

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 John Wiley & Sons, Ltd
  • (PMID = 15959923.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons
  •  go-up   go-down


70. Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R, Hernandez-Lain A, Cabello A, Ramos A, Gonzalez Leon P, Ricoy Campo JR: Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis. Clin Neuropathol; 2009 Jan-Feb;28(1):11-20
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis.
  • BACKGROUND: The clinical course of oligodendroglial tumors is variable and there is a lack of consensus with regard to precisely diagnose which minimal criteria are required to make a diagnosis of a high-grade oligodendrial tumor.
  • The aims of the present study are to assess pathologic factors with prognostic significance, in addiction to clinical and neuroradiologic variables, in an attempt to identify reproducible histological parameters that are useful for classification of oligodendroglial tumors.
  • METHODS: 80 oligodendroglial tumors diagnosed between 1977 and 2004 were analyzed.
  • To make a diagnosis of anaplastic tumor we used reproducible parameters: endothelial proliferation, high cellularity, increased mitotic activity and necrosis.
  • Oligoastrocytomas (mixed gliomas) were diagnosed when the astrocytic component was clearly identified as part of the neoplastic cell population.
  • CONCLUSIONS: Clear cut histopathological criteria (endothelial proliferation, high cellularity, mitotic activity and necrosis) allow to establish different oligodendroglial tumor entities with distinct survival outcome.
  • [MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / pathology. Oligodendroglioma / classification. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Neuropathol. 2009 Mar-Apr;28(2):150
  • (PMID = 19216215.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


71. Wrensch M, Kelsey KT, Liu M, Miike R, Moghadassi M, Sison JD, Aldape K, McMillan A, Wiemels J, Wiencke JK: ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol; 2005 Oct;7(4):495-507
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERCC1 and ERCC2 polymorphisms and adult glioma.
  • We genotyped constitutive variants ERCC1 C8092A and ERCC2 K751Q and R156R in approximately 450 adults with glioma and 500 controls from two independent population-based series, uniformly reviewed patients' tumors to determine histopathologic category, and determined a variety of tumor markers among astrocytic tumors.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Mol Genet Genomics. 2001 Aug;265(6):1087-96 [11523781.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):295-9 [11872635.001]
  • [Cites] Genome Res. 2002 Mar;12(3):436-46 [11875032.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1377-81 [11888908.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Carcinogenesis. 2002 Apr;23(4):599-603 [11960912.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 15;32(12):1244-53 [12057762.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):123-9 [12399122.001]
  • [Cites] Mutagenesis. 2002 Nov;17(6):463-9 [12435843.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 [12496039.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):359-65 [12692111.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):669-73 [12740916.001]
  • [Cites] J Occup Environ Med. 2003 Jun;45(6):639-47 [12802217.001]
  • [Cites] Nature. 2003 Jul 10;424(6945):228-32 [12853965.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):333-7 [12865926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):461-7 [15006924.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2251-7 [15026370.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):65-73 [15199548.001]
  • [Cites] Toxicol Lett. 2004 Dec 1;154(1-2):133-42 [15475187.001]
  • [Cites] Carcinogenesis. 1984 Apr;5(4):511-4 [6705149.001]
  • [Cites] Biochemistry. 1989 Oct 3;28(20):7979-84 [2690930.001]
  • [Cites] J Bacteriol. 1991 Jun;173(11):3419-24 [1710617.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] Chromosoma. 1997 Dec;106(8):493-502 [9426281.001]
  • [Cites] Yeast. 1999 Feb;15(3):205-18 [10077187.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2929-35 [10082560.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):345-50 [10209947.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):267-75 [15637390.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):45-54; quiz 57 [15661686.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):969-76 [15824172.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):44-50 [10708517.001]
  • [Cites] Cancer Lett. 2000 Apr 14;151(2):187-92 [10738113.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):551-5 [10753184.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):843-7 [10952103.001]
  • [Cites] Carcinogenesis. 2000 Dec;21(12):2219-23 [11133811.001]
  • [Cites] Lupus. 2000;9(9):681-7 [11199923.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1354-7 [11245433.001]
  • [Cites] Environ Mol Mutagen. 2001;37(3):241-83 [11317342.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60 [11319176.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3949-54 [11358811.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):911-2 [11489761.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):159-66 [11850545.001]
  • (PMID = 16212814.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA052689; United States / NCI NIH HHS / CA / P50CA097257; United States / NCI NIH HHS / CA / R01CA52689
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  • [Other-IDs] NLM/ PMC1871723
  •  go-up   go-down


72. Nasonkin I, Mahairaki V, Xu L, Hatfield G, Cummings BJ, Eberhart C, Ryugo DK, Maric D, Bar E, Koliatsos VE: Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum. Stem Cells; 2009 Oct;27(10):2414-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum.
  • Human embryonic stem cells (HESCs) are a rich source of neural precursors (NPs) for grafting, but have been questioned for their tendency to form tumors.
  • Here we studied the ability of HESC-derived NP grafts optimized for cell number and differentiation stage prior to transplantation, to survive and stably differentiate and integrate in the basal forebrain (neostriatum) of young adult nude rats over long periods of time (6 months).
  • NPs inoculated in white matter tracts showed a tendency toward glial (primarily astrocytic) differentiation, whereas NPs inoculated in the ventricular epithelium persisted as nestin(+) precursors.
  • Our findings demonstrate the long-term ability of noggin-derived human NPs to structurally integrate tumor-free into the mature mammalian forebrain, while maintaining some cell fate plasticity that is strongly influenced by particular central nervous system (CNS) niches.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cereb Cortex. 2000 Aug;10(8):729-47 [10920046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16707-12 [18922775.001]
  • [Cites] Neuron. 2000 Dec;28(3):713-26 [11163261.001]
  • [Cites] Development. 2001 Oct;128(19):3759-71 [11585802.001]
  • [Cites] Nat Biotechnol. 2001 Dec;19(12):1129-33 [11731781.001]
  • [Cites] Nat Rev Neurosci. 2002 Apr;3(4):271-80 [11967557.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):865-75 [12372282.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):167-74 [12514213.001]
  • [Cites] BMC Neurosci. 2001;2:9 [11399205.001]
  • [Cites] J Cell Biol. 2003 Jun 9;161(5):911-21 [12796477.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):417-24 [12849120.001]
  • [Cites] Stem Cells. 2003;21(5):521-6 [12968106.001]
  • [Cites] BMC Neurosci. 2003 Oct 22;4:27 [14572319.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12543-8 [15310843.001]
  • [Cites] Neuroscience. 1986 Oct;19(2):465-93 [3022187.001]
  • [Cites] Nature. 1990 Oct 11;347(6293):556-8 [1699131.001]
  • [Cites] Prog Brain Res. 1990;82:391-9 [1705355.001]
  • [Cites] Brain Res. 1994 Dec 30;668(1-2):211-9 [7704606.001]
  • [Cites] Dev Biol. 1995 Apr;168(2):342-57 [7729574.001]
  • [Cites] Exp Neurol. 1996 Jan;137(1):15-25 [8566206.001]
  • [Cites] Mech Dev. 1996 Sep;59(1):89-102 [8892235.001]
  • [Cites] J Neurosci. 1997 Aug 1;17(15):5858-67 [9221783.001]
  • [Cites] Nature. 1997 Dec 18-25;390(6661):680-3 [9414159.001]
  • [Cites] Genes Dev. 1998 May 15;12(10):1438-52 [9585504.001]
  • [Cites] Stem Cells. 2004;22(6):925-40 [15536184.001]
  • [Cites] Nat Biotechnol. 2005 Feb;23(2):215-21 [15685164.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2475-85 [15743839.001]
  • [Cites] Nat Biotechnol. 2005 May;23(5):601-6 [15852001.001]
  • [Cites] J Neurosci. 2005 May 11;25(19):4694-705 [15888645.001]
  • [Cites] Stem Cells Dev. 2005 Jun;14(3):266-9 [15969621.001]
  • [Cites] J Neurosci. 2005 Sep 21;25(38):8714-24 [16177041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14069-74 [16172374.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1234-41 [16002783.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1242-50 [16210408.001]
  • [Cites] Neuron. 2006 Jan 5;49(1):41-53 [16387638.001]
  • [Cites] Neuron. 2006 Jan 5;49(1):55-66 [16387639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1319-24 [16432194.001]
  • [Cites] Stem Cells. 2006 Jan;24(1):125-38 [16100006.001]
  • [Cites] Stem Cells Dev. 2006 Apr;15(2):254-9 [16646671.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1583-93 [16543488.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1433-40 [16556709.001]
  • [Cites] Exp Neurol. 2006 Oct;201(2):525-9 [16806174.001]
  • [Cites] Curr Opin Genet Dev. 2006 Oct;16(5):455-62 [16920351.001]
  • [Cites] Transplantation. 2006 Oct 15;82(7):865-75 [17038899.001]
  • [Cites] Eur J Neurosci. 2006 Oct;24(7):1885-96 [17067292.001]
  • [Cites] Dev Cell. 2006 Dec;11(6):831-44 [17141158.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):411-8 [17038668.001]
  • [Cites] J Neurosci. 2007 Feb 21;27(8):1836-52 [17314281.001]
  • [Cites] Neurobiol Aging. 2007 Aug;28(8):1148-62 [16859812.001]
  • [Cites] Glia. 2007 Aug 15;55(11):1156-68 [17597119.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1931-9 [17478583.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e39 [17298165.001]
  • [Cites] J Neurosci. 2007 Nov 21;27(47):12787-96 [18032650.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Expert Opin Biol Ther. 2008 Feb;8(2):137-41 [18194070.001]
  • [Cites] Curr Protoc Neurosci. 2005 Nov;Chapter 3:Unit 3.18 [18428621.001]
  • [Cites] EMBO J. 2000 Oct 16;19(20):5460-72 [11032813.001]
  • (PMID = 19609935.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC000232; United States / NINDS NIH HHS / NS / R01 NS045140; United States / NINDS NIH HHS / NS / NS45140-03; United States / NEI NIH HHS / EY / P30 EY001765; United States / NIDCD NIH HHS / DC / DC000232-23; United States / NIDCD NIH HHS / DC / R01 DC000232-23; United States / NIDCD NIH HHS / DC / DC005211-089002; United States / NIDCD NIH HHS / DC / R01 DC000232; United States / NIDCD NIH HHS / DC / P30 DC005211; United States / NINDS NIH HHS / NS / R01 NS045140-03; United States / NEI NIH HHS / EY / EY01765; United States / NINDS NIH HHS / NS / NS045140-03; United States / NIDCD NIH HHS / DC / P30 DC005211-089002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Phosphoproteins; 148294-77-3 / noggin protein
  • [Other-IDs] NLM/ NIHMS193803; NLM/ PMC2906132
  •  go-up   go-down


73. Alameda F, Lloreta J, Ariza A, Salido M, Espinet B, Baro T, Garcia-Fructoso G, Galito E, Munne A, Cruz Sanchez FF, Sole F, Serrano S: Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case. Clin Neuropathol; 2007 Jan-Feb;26(1):12-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the central nervous system with glial differentiation: a FISH study of an adult case.
  • Primitive neuroectodermal tumors (PNETs) of the central nervous system (CNS), a rare occurrence in adults, may show glial differentiation and can be misinterpreted as pure astrocytic neoplasms.
  • Few fluorescence in situ hybridization (FISH) studies have been carried out on these tumors; isochromosome 17q was found to be the major chromosomal abnormality.
  • We present the case of an adult in which we performed a FISH study of both the glial and neuronal components.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 17 / genetics. Neuroectodermal Tumors, Primitive / genetics. Neuroectodermal Tumors, Primitive / pathology. Trisomy / genetics
  • [MeSH-minor] Adult. Humans. In Situ Hybridization, Fluorescence. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290931.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


74. Choi YL, Kim CJ, Matsuo T, Gaetano C, Falconi R, Suh YL, Kim SH, Shin YK, Park SH, Chi JG, Thiele CJ: HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors. J Neurooncol; 2005 May;73(1):19-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors.
  • HUlip is highly expressed only in the fetal brain and spinal cord, and is undetected in the adult brain.
  • The purpose of this study was to investigate the pattern of hUlip expression in the developing human brain and nervous system tumors.
  • Ten human brains at different developmental stages and 118 cases of nervous system tumor tissues were examined by immunohistochemistry.
  • Twelve related tumor cell lines were also analyzed by northern blotting and immunoblotting.
  • HUlip was expressed in late fetal and early postnatal brains; strongly in the neurons of the brain stem, basal ganglia/thalamus, and dentate gyrus of the hippocampus, and relatively weakly in the cerebral and cerebellar cortex.
  • Among tumors, hUlip expression was easily detected in tumor cells undergoing neuronal differentiation such as ganglioneuroblastomas and ganglioneuromas.
  • Furthermore, hUlip immunoreactivity was also found in various brain tumors showing neuronal differentiation: central neurocytomas (6 of 6 cases were positive), medulloblastomas (5/11), atypical teratoid rhabdoid tumor (1/1) and gangliogliomas (4/7).
  • Some astrocytic tumors also showed weak positivity: astrocytomas (1 of 5 cases), anaplastic astrocytomas (2/5), and glioblastomas (3/11).
  • The results of this study indicate that the expression of hUlip protein is distinctly restricted to the late fetal and early postnatal periods of human nervous system development and to certain subsets of nervous system tumors.
  • The exact function of hUlip needs to be further clarified; yet the results of our study strongly imply that hUlip function is important in human nervous system development and its aberrant expression in various types of nervous system tumors suggests a role of hUlip as an oncofetal neural antigen.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Developmental / physiology. Gene Expression Regulation, Neoplastic / physiology. Muscle Proteins / metabolism
  • [MeSH-minor] Astrocytes / cytology. Astrocytes / metabolism. Cell Differentiation / genetics. Cell Differentiation / physiology. Cell Line, Tumor. Female. Gestational Age. Humans. Immunohistochemistry. Male. Neuroblastoma / genetics. Neuroblastoma / metabolism. Neurons / cytology. Neurons / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933812.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DPYSL3 protein, human; 0 / Muscle Proteins
  •  go-up   go-down


75. Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O'Dorisio T, Bushnell D, Madsen M: Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med; 2010 Oct;51(10):1524-31
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.
  • The purpose of this study was to conduct a phase I trial of (90)Y-DOTATOC to determine the dose-toxicity profile in children and young adults with somatostatin receptor-positive tumors.
  • RESULTS: Seventeen subjects (age, 2-24 y) received at least 1 dose of (90)Y-DOTATOC; diagnoses included neuroblastoma, embryonal and astrocytic brain tumors, paraganglioma, multiple endocrine neoplasia IIB, and neuroendocrine tumors.
  • CONCLUSION: Peptide receptor radionuclide therapy with (90)Y-DOTATOC is safe in children and young adults and demonstrated a 12% partial response plus 29% minor response rate in patients with somatostatin receptor-positive tumors.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:55S-61S [15653652.001]
  • [Cites] J Nucl Med. 1999 May;40(5):762-7 [10319747.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:83S-91S [15653656.001]
  • [Cites] Pediatr Blood Cancer. 2005 Mar;44(3):232-9 [15490487.001]
  • [Cites] Pituitary. 2006;9(3):243-8 [17001462.001]
  • [Cites] Oncology (Williston Park). 2006 Nov;20(12):1537-43; discussion 1544-5, 1549 [17153907.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Jun;21(3):561-73; x [17548040.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Feb;22(1):130-5 [17627421.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1219-27 [17260141.001]
  • [Cites] Lancet Neurol. 2007 Dec;6(12):1073-85 [18031705.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):561-6 [17387742.001]
  • [Cites] Genes Dev. 2008 Feb 15;22(4):436-48 [18281460.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2124-30 [18445841.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [Cites] J Nucl Med. 2009 Sep;50(9):1427-34 [19690033.001]
  • [Cites] Endocr Relat Cancer. 2010 Mar;17(1):R53-73 [19995807.001]
  • [Cites] Eur J Nucl Med. 1999 Nov;26(11):1439-47 [10552085.001]
  • [Cites] Regul Pept. 2000 Mar 17;88(1-3):61-73 [10706954.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):836-46 [11504080.001]
  • [Cites] Eur J Nucl Med. 2001 Dec;28(12):1743-50 [11734910.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):9-15 [12483404.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):207-16 [12552338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):28-39 [12694821.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Aug;18(4):619-25 [14503958.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10):1556-60 [14530466.001]
  • [Cites] Nucl Med Commun. 2004 Mar;25(3):253-7 [15094443.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2997-3006 [15131035.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1386-92 [15175836.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2324-9 [7902425.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):152-6 [8271037.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47 [9262252.001]
  • [Cites] Lancet. 1998 Feb 7;351(9100):417-8 [9482300.001]
  • [Cites] Pediatr Res. 1999 May;45(5 Pt 1):697-708 [10231868.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:62S-6S [15653653.001]
  • (PMID = 20847174.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA91578; United States / FDA HHS / FD / R01 FD002595; United States / FDA HHS / FD / R01FD002595; United States / NCI NIH HHS / CA / R01 CA167632; United States / NCI NIH HHS / CA / R21 CA091578
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 90Y-octreotide, DOTA-Tyr(3)-; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ NIHMS495708; NLM/ PMC3753801
  •  go-up   go-down


76. Jacques TS, Swales A, Brzozowski MJ, Henriquez NV, Linehan JM, Mirzadeh Z, O' Malley C, Naumann H, Alvarez-Buylla A, Brandner S: Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO J; 2010 Jan 6;29(1):222-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes.
  • It has been suggested that intrinsic brain tumours originate from a neural stem/progenitor cell population in the subventricular zone of the post-natal brain.
  • However, the influence of the initial genetic mutation on the phenotype as well as the contribution of mature astrocytes to the formation of brain tumours is still not understood.
  • We deleted Rb/p53, Rb/p53/PTEN or PTEN/p53 in adult subventricular stem cells; in ectopically neurografted stem cells; in mature parenchymal astrocytes and in transplanted astrocytes.
  • We found that only stem cells, but not astrocytes, gave rise to brain tumours, independent of their location.
  • This suggests a cell autonomous mechanism that enables stem cells to generate brain tumours, whereas mature astrocytes do not form brain tumours in adults.
  • Our study underlines an important role of stem cells and the relevance of initial genetic mutations in the pathogenesis and phenotype of brain tumours.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):135-45 [18691548.001]
  • [Cites] Nat Med. 2009 Jan;15(1):110-6 [19122659.001]
  • [Cites] Genes Dev. 2009 Jan 15;23(2):157-70 [19171780.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):514-26 [19477430.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:357-65 [19022766.001]
  • [Cites] Neurosci Lett. 1999 Dec 10;276(3):197-200 [10612639.001]
  • [Cites] Curr Opin Genet Dev. 2000 Feb;10(1):94-9 [10679383.001]
  • [Cites] Genes Dev. 2000 Apr 15;14(8):994-1004 [10783170.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Nat Neurosci. 2000 Nov;3(11):1091-7 [11036265.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] EMBO Rep. 2001 Apr;2(4):292-7 [11306549.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3826-36 [11325859.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9209-14 [11481484.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6674-8 [11559533.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):157-68 [12086874.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Development. 2002 Jul;129(14):3513-22 [12091320.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):1-7 [12406541.001]
  • [Cites] Neuron. 2002 Dec 19;36(6):1021-34 [12495619.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):133-46 [12957288.001]
  • [Cites] Neuron. 2004 Jun 24;42(6):885-8 [15207233.001]
  • [Cites] Nucleic Acids Res. 1997 May 1;25(9):1766-73 [9108159.001]
  • [Cites] Oncogene. 1998 Jul 9;17(1):1-12 [9671308.001]
  • [Cites] Development. 1998 Aug;125(16):3167-77 [9671589.001]
  • [Cites] J Neurobiol. 1998 Aug;36(2):105-10 [9712298.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3644-9 [9851971.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6937-41 [10359817.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2065-9 [15781613.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5172-80 [15958561.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Development. 2005 Dec;132(24):5577-88 [16314489.001]
  • [Cites] Neuron. 2006 Jul 20;51(2):187-99 [16846854.001]
  • [Cites] J Neurosci. 2006 Sep 13;26(37):9593-602 [16971543.001]
  • [Cites] Methods Enzymol. 2006;419:3-23 [17141049.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Science. 2007 Jul 20;317(5836):381-4 [17615304.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):328-41 [17936558.001]
  • [Cites] Genesis. 2007 Dec;45(12):768-75 [18064676.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3286-94 [18451155.001]
  • [Cites] Neuron. 2008 Jun 26;58(6):832-46 [18579075.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • (PMID = 19927122.001).
  • [ISSN] 1460-2075
  • [Journal-full-title] The EMBO journal
  • [ISO-abbreviation] EMBO J.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD032116; United States / NICHD NIH HHS / HD / R37 HD032116; United States / NICHD NIH HHS / HD / HD-32116
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / glial fibrillary astrocytic protein, mouse; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2808375
  •  go-up   go-down


77. Wiencke JK, Aldape K, McMillan A, Wiemels J, Moghadassi M, Miike R, Kelsey KT, Patoka J, Long J, Wrensch M: Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev; 2005 Jul;14(7):1774-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.
  • BACKGROUND: Risk factors for adult glioma in the San Francisco Bay Area include well-known demographic features such as age and race/ethnicity, and our previous studies indicated that these characteristics are associated with the TP53 mutation status of patients' tumors.
  • METHODS: Molecular analyses were carried out on 556 incident astrocytic tumors.
  • RESULTS: The tumor data confirm the inverse relationships between TP53 mutation and MDM2 (P = 0.04) or EGFR (P = 0.004) amplification and that patients whose tumors contain TP53 mutations are younger than those without (P < 0.001).
  • Carriers of the MGMT variant 84Phe allele were significantly less likely to have tumors with TP53 overexpression (odds ratio, 0.30; 95% confidence interval, 0.13-0.71) and somewhat less likely to have tumors with any TP53 mutation (odds ratio, 0.47; 95% confidence interval, 0.13-1.69) after adjusting for age, gender, and ethnicity.
  • The data on MGMT show that an inherited factor involving the repair of methylation and other alkylation damage, specifically to the O6 position of guanine, may be associated with the development of tumors that proceed in their development without TP53 mutations or accumulation of TP53 protein and possibly also those that do not involve amplification of the EGFR locus.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Ethnic Groups. Female. Gene Amplification. Genes, p53. Humans. Male. Middle Aged. Prevalence. Proto-Oncogene Proteins c-mdm2. San Francisco / epidemiology. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030116.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES04705; United States / NIEHS NIH HHS / ES / ES06717; United States / NCI NIH HHS / CA / P50CA097257; United States / NCI NIH HHS / CA / R01CA52689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


78. Jeuken JW, van der Maazen RW, Wesseling P: Molecular diagnostics as a tool to personalize treatment in adult glioma patients. Technol Cancer Res Treat; 2006 Jun;5(3):215-29
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics as a tool to personalize treatment in adult glioma patients.
  • Gliomas, the most frequent primary brain tumors in humans, form a heterogeneous group, encompassing many different histological types and malignancy grades.
  • The major representatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors.
  • After summarizing the most relevant genetic aberrations and pathways in these tumors detected up till now, this review will discuss the clinical relevance of this information.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioma / genetics. Molecular Diagnostic Techniques
  • [MeSH-minor] Cell Cycle Proteins / genetics. DNA Methylation. DNA Repair. Gene Dosage. Humans. Neovascularization, Pathologic. Receptor Protein-Tyrosine Kinases / genetics. Retinoblastoma Protein / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700618.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 94
  •  go-up   go-down


79. Samaras V, Piperi C, Korkolopoulou P, Zisakis A, Levidou G, Themistocleous MS, Boviatsis EI, Sakas DE, Lea RW, Kalofoutis A, Patsouris E: Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol Cell Biochem; 2007 Oct;304(1-2):343-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors.
  • Identification of markers of aggressiveness in this tumor could represent new therapeutic targets.
  • IL-6 and IL-10 secretion levels were determined using ELISPOT methodology in peripheral blood mononuclear cells of 18 patients with astrocytic neoplasms (3 grade II and 15 grade IV), in parallel with 18 healthy controls.
  • In addition, IL-10 secretion from peripheral mononuclear and tumor cells of glioma patients was also higher as compared to healthy controls (P = 0.0002).
  • Based on immunohistochemical staining, IL-6 expression was localized in tumor cells and macrophages as well as in areas of large ischemic necrosis, while the major source of IL-10 expression in glioblastomas was the microglia/macrophage cells.
  • [MeSH-major] Astrocytoma / blood. Brain Neoplasms / blood. Enzyme-Linked Immunosorbent Assay / methods. Interleukin-10 / blood. Interleukin-10 / secretion. Interleukin-6 / blood. Interleukin-6 / secretion
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Glioblastoma / blood. Humans. Leukocytes / secretion. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551671.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


80. De Tommasi A, De Tommasi C, Occhiogrosso G, Cimmino A, Parisi M, Sanguedolce F, Ciappetta P: Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature. Eur J Neurol; 2006 Mar;13(3):240-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature.
  • Spinal primitive neuroectodermal tumors (PNET) are very rare tumors, and intramedullary localization is even less common.
  • Following the WHO 2000 classification, PNETs have been considered embryonal tumors composed of undifferentiated neuroepithelial cells with a capacity of differentiation into different cellular lines, such as astrocytic, ependymal, melanotic and muscular.
  • The optimal treatment for these malignant tumors is not yet clear, although, over the years, radiotherapy has been considered the best treatment for spinal PNETs.
  • The patient, 18 months after the onset of his symptomatology, died without cerebral tumor involvement.
  • [MeSH-major] Brain Neoplasms. Laminectomy / methods. Neuroectodermal Tumors, Primitive
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618339.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


81. Kordes U, Hagel C: Expression of SOX9 and SOX10 in central neuroepithelial tumor. J Neurooncol; 2006 Nov;80(2):151-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of SOX9 and SOX10 in central neuroepithelial tumor.
  • We have examined the pattern of expression for SOX9 and SOX10 in primary brain tumors by immunohistochemistry.
  • Pediatric and adult high grade tumors display strong nuclear staining for both SOX9 and SOX10 (astrocytic, oligodendroglial and primitive neuroectodermal tumors).
  • [MeSH-minor] Adolescent. Adult. Astrocytes / metabolism. Cell Nucleus / pathology. Child. Child, Preschool. Gene Expression Regulation, Neoplastic / genetics. Gliosis / pathology. Humans. Immunohistochemistry. Oligodendroglia / metabolism. Paraffin Embedding. SOX9 Transcription Factor. SOXE Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791471.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / High Mobility Group Proteins; 0 / SOX10 protein, human; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human; 0 / SOXE Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


82. Min HS, Kim B, Park SH: Array-based comparative genomic hybridization and immunohistochemical studies in gliomatosis cerebri. J Neurooncol; 2008 Dec;90(3):259-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri (GC) are extensively infiltrative glial tumors classified as astrocytic tumors in the current World Health Organization (WHO) classification scheme.
  • In histological and immunohistochemical review, 18 cases (64%) were of astrocytic lineage, three (11%) were of oligodendroglial lineage, and seven (25%) were of uncommitted lineage.
  • These altered genetic foci are not known to be involved in the development of conventional glial tumors, including astrocytic tumors.
  • In conclusion, despite the dominant astrocytic differentiation of GC histologically, novel genomic aberrations found in our GC cases were different from those of astrocytic tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / metabolism. Child. Child, Preschool. Cluster Analysis. DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Infant. Infant, Newborn. Intermediate Filament Proteins / metabolism. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Nestin. Receptor, Epidermal Growth Factor / metabolism. Retrospective Studies. Survival Analysis. Tumor Suppressor Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18704270.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


83. Vogazianou AP, Chan R, Bäcklund LM, Pearson DM, Liu L, Langford CF, Gregory SG, Collins VP, Ichimura K: Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol; 2010 Jul;12(7):664-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the status of chromosomes 1 and 19 in 363 astrocytic and oligodendroglial tumors.
  • Whereas the predominant pattern of copy number abnormality was a concurrent loss of the entire 1p and 19q regions (total 1p/19q loss) among oligodendroglial tumors and partial deletions of 1p and/or 19q in astrocytic tumors, a subset of apparently astrocytic tumors also had total 1p/19q loss.
  • The presence of total 1p/19q loss was associated with longer survival of patients with all types of adult gliomas independent of age and diagnosis (P = .041).
  • The most commonly deleted region on 19q in astrocytic tumors spans 885 kb in 19q13.33-q13.41, which is telomeric to the previously proposed region.
  • Deletion mapping of the centromeric regions of 1p and 19q in the tumors that had total 1p/19q loss, indicating that the breakpoints lie centromeric to NOTCH2 within the pericentromeric regions of 1p and 19q.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Jun 6;21(25):3961-8 [12037678.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Nat Rev Neurosci. 2006 Feb;7(2):93-102 [16429119.001]
  • [Cites] Nature. 2006 May 18;441(7091):315-21 [16710414.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9428-36 [17018597.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] Cancer Lett. 2007 Feb 8;246(1-2):82-91 [16556484.001]
  • [Cites] Nat Rev Immunol. 2007 Apr;7(4):255-66 [17380156.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] PLoS One. 2007;2(6):e576 [17593975.001]
  • [Cites] J Appl Genet. 2007;48(3):261-8 [17666779.001]
  • [Cites] Brain Pathol. 2007 Oct;17(4):363-70 [17610521.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4705-12 [11156223.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):184-204 [11294823.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Cell Signal. 2002 May;14(5):381-95 [11882383.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4100-8 [12124348.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Oct;35(2):97-112 [12203773.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):476-87 [12600941.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7600-5 [14633674.001]
  • [Cites] Nature. 2004 Apr 1;428(6982):529-35 [15057824.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jun;151(2):182-3 [15172758.001]
  • [Cites] J Neurooncol. 1995;23(3):249-52 [7673988.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):9-15 [9591629.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15 [18091559.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1041-50 [10515227.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1778-86 [18076069.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2097-108 [17934521.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2503-10 [18302158.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):355-64 [18394558.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18255-60 [19017811.001]
  • [Cites] PLoS One. 2009;4(1):e4107 [19119320.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):458-65 [19147558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3420-5 [19223589.001]
  • [Cites] Cancer Sci. 2009 May;100(5):920-6 [19445024.001]
  • [Cites] Brain Pathol. 1999 Oct;9(4):639-43 [10517502.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):638-55 [15322700.001]
  • (PMID = 20164239.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / A6618; United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2940668
  •  go-up   go-down


84. Yao Y, Tang X, Li S, Mao Y, Zhou L: Brain tumor stem cells: view from cell proliferation. Surg Neurol; 2009 Mar;71(3):274-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells: view from cell proliferation.
  • A small population of TSCs, which form neurospheres and possess the capacity for self-renewal, has been recently identified in adult and pediatric brain tumors.
  • They differentiate into phenotypically diverse populations, including neuronal, astrocytic, and oligodendroglial cells in vitro and recapitulate original tumors in vivo.
  • The understanding of brain TSCs has been greatly advanced by the knowledge of cell proliferation, which contributes to initiate and sustain the malignant phenotype.
  • In this article, the authors summarized the evidence of the presence of TSCs in human brain tumors and emphasized the significance of the proliferative status of TSCs.
  • Finally, the preliminary evidence that TSCs in malignant brain tumors have more proliferative capacity than stem/progenitor cells in benign brain tumors was discussed.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249579.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


85. Ren XH, Cui XL, Lin S, Wang ZC: [The correlation between combining 1p/19q LOH and pathology in gliomas]. Zhonghua Yi Xue Za Zhi; 2010 Jul 6;90(25):1781-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumor samples from 127 glioma patients were collected.
  • RESULTS: The frequencies of combining 1p/19q LOH in astrocytic, oligoastrocytic and oligodendroglial tumors were 19.30%, 50.00% and 80.77% respectively.
  • The frequencies of combining 1p/19q LOH in oligoastrocytic and oligodendroglial tumors were higher than those in astrocytic tumors (P < 0.01) and the frequencies of combining 1p/19q LOH in oligodendroglial tumors was higher than those in oligoastrocytic tumors (P < 0.05).
  • The frequencies of 1p/19q LOH in astrocytic, oligoastrocytic and oligodendroglial tumors were 12.28%, 11.36 and 0 respectively.
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Female. Humans. Male. Middle Aged. Oligodendroglia / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979900.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


86. Srinivas BH, Uppin MS, Panigrahi MK, Vijaya Saradhi M, Jyotsna Rani Y, Challa S: Pleomorphic xanthoastrocytoma of the pineal region. J Clin Neurosci; 2010 Nov;17(11):1439-41
Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytomas are indolent, astrocytic tumors usually located in the superficial cerebral cortex.
  • We describe a patient with an astrocytic tumor arising in the pineal region that fulfilled all of the morphologic and immunohistochemical criteria of a pleomorphic xanthoastrocytoma.
  • [MeSH-minor] Adult. Diagnosis, Differential. Headache / diagnosis. Headache / etiology. Humans. Magnetic Resonance Imaging / methods. Male. Ocular Motility Disorders / diagnosis. Ocular Motility Disorders / etiology. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Tomography, X-Ray Computed / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20655751.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


87. Fernandez A, Karavitaki N, Ansorge O, Fazal-Sanderson V, Wass JA: Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? Pituitary; 2008;11(3):325-30
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In astrocytic-cell tumors, the role of autocrine and paracrine IGF-I expression in enhancing tumoral progression is well established.
  • However, the influence of systemic IGF-I levels on the clinical behavior of astrocytic neoplasms remains an open subject of research.
  • The coexistence of systemic IGF-I hypersecretion with a quick progression in the histopathological grade of the astrocytoma raises the compelling question of whether the clinical behavior of the astrocytic tumor was influenced by the acromegalic status.
  • The role of IGF-I signaling in the pathogenesis of astrocytic-cell tumors and the experience with therapeutic strategies addressing this pathway in astrocytomas are also discussed.
  • [MeSH-major] Acromegaly / complications. Astrocytoma / complications. Brain Neoplasms / complications
  • [MeSH-minor] Adult. Cranial Irradiation. Craniotomy. Disease Progression. Ergolines / therapeutic use. Humans. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Male. Neoplasm Staging. Peptides, Cyclic / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Treatment Outcome. Up-Regulation

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18000757.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ergolines; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; LL60K9J05T / cabergoline
  •  go-up   go-down


88. Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D, Siegal T: Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res; 2007 Mar 1;13(5):1429-37
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Because little is known about the evolution of genetic and epigenetic changes that occur during tumor progression in oligodendrogliomas, we evaluated these changes in paired early and progressive oligodendrogliomas.
  • RESULTS: In early tumors, 60.8% were of low grade compared with only 17% low-grade tumors at recurrence.
  • Of 17 early tumors described as pure oligodendrogliomas, 76.5% remained in this lineage, regardless of their grade, whereas others changed to astrocytic tumors.
  • Oligoastrocytic tumors had a significantly higher tendency to transform to astrocytic tumors.
  • All pure oligodendrogliomas with 1p/19q codeletions remained phenotypically unchanged, unlike mixed tumors with codeletions, of which 83% changed their cell lineage.
  • Of tumors with early 1p deletion, 80% remained oligodendroglial at progression, whereas 75% of tumors with an intact 1p changed to astrocytic phenotype.
  • 10q loss was uncommon in both early and progressive tumors.
  • The proportional gain in methylation at progression was 31% for tumors with early 1p deletion, unlike tumors with an intact 1p, which had an 87.5% gain of methylation at progression.
  • CONCLUSIONS: Pure oligodendrogliomas with 1p/19q deletion tend to retain their cell phenotype and genetic profile unlike tumors with no deletions or mixed histology.
  • MGMT promoter methylation is more pronounced at tumor progression, particularly in tumors with an intact 1p.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Methylation. Epigenesis, Genetic. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Female. Humans. Immunohistochemistry. Male. Microsatellite Repeats. Middle Aged. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17332285.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


89. Yan B, Chour HH, Peh BK, Lim C, Salto-Tellez M: RhoA protein expression correlates positively with degree of malignancy in astrocytomas. Neurosci Lett; 2006 Oct 23;407(2):124-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astrocytic tumors are the most common intracranial neoplasms.
  • A molecular marker that provides an objective reference for classification and prognostication of astrocytic tumors would be useful in diagnostic pathology.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. rhoA GTP-Binding Protein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Neoplasm Invasiveness / pathology. Paraffin Embedding. Tissue Fixation. Up-Regulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978776.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


90. Mendonça R, Lima LG, Fernandes LN, Ferreira NP, De Napoli G: [Primary connus medullaris glioblastoma: case report]. Arq Neuropsiquiatr; 2005 Jun;63(2B):539-42
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastomas are the most common type of brain tumors; astrocytic in their origin, they are anaplastic tumors, and are located mainly in the cerebral hemispheres.
  • Primary growth in the conus medullaris is very rare, and the assessment and prognosis of this kind of tumor are distinct and unique.
  • We present here the case of a 39 years-old man with an intramedullary tumor of the spinal cord, with an histo pathological diagnosis of glioblastoma, along with some therapeutic considerations.
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16059615.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


91. Hede SM, Hansson I, Afink GB, Eriksson A, Nazarenko I, Andrae J, Genove G, Westermark B, Nistér M: GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background. Glia; 2009 Aug 15;57(11):1143-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background.
  • Glioblastomas are the most common and malignant astrocytic brain tumors in human adults.
  • The tumor suppressor gene TP53 is commonly mutated and/or lost in astrocytic brain tumors and the TP53 alterations are often found in combination with excessive growth factor signaling via PDGF/PDGFRalpha.
  • Here, we have generated transgenic mice over-expressing human PDGFB in brain, under control of the human GFAP promoter.
  • These mice showed no phenotype, but on a Trp53 null background a majority of them developed brain tumors.
  • This occurred at 2-6 months of age and tumors displayed human glioblastoma-like features with integrated development of Pdgfralpha+ tumor cells and Pdgfrbeta+/Nestin+ vasculature.
  • The transgene was expressed in subependymal astrocytic cells, in glia limitans, and in astrocytes throughout the brain substance, and subsequently, microscopic tumor lesions were initiated equally in all these areas.
  • With tumor size, there was an increase in Nestin positivity and variability in lineage markers.
  • These results indicate an unexpected plasticity of all astrocytic cells in the adult brain, not only of SVZ cells.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / genetics. Genes, p53. Glial Fibrillary Acidic Protein / genetics. Glioblastoma / genetics. Promoter Regions, Genetic. Proto-Oncogene Proteins c-sis / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115382.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Proto-Oncogene Proteins c-sis; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


92. Komatani H, Sugita Y, Arakawa F, Ohshima K, Shigemori M: Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: an accelerated growth factor in glioblastomas. Int J Oncol; 2009 Mar;34(3):665-72
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To elucidate the correlation between the CXCR4/CXCL12 axis and glioblastomas (GBs), the present study assessed CXCR4/CXCL12 expression in 44 astrocytic tumor tissues using immunohistochemical analyses.
  • Several cell lines of brain tumors were also analyzed by RT-PCR analyses.
  • Although low-grade, astrocytic tumors were rarely positive for CXCL12 immunohistochemically, all GBs showed moderate to intense immunostaining with CXCL12, with particularly intense immunostaining being observed in the pseudopalisading cells and the proliferating microvessels.
  • Regarding CXCR4, widespread positive immunoreactivity was noted in the tumor cells in almost all cases of GBs.
  • Taken together, these results suggest that secretion of CXCR4/CXCL12 by hypoxic pseudopalisading and proliferating microvascular cells contributes to an outward migration of tumor cells away from hypoxia, creating a peripherally moving wave and subsequent microvascular proliferation.
  • [MeSH-major] Brain Neoplasms / blood supply. Chemokine CXCL12 / biosynthesis. Glioblastoma / blood supply
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / blood supply. Astrocytoma / pathology. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Child. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212671.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chemokine CXCL12
  •  go-up   go-down


93. Colodner KJ, Montana RA, Anthony DC, Folkerth RD, De Girolami U, Feany MB: Proliferative potential of human astrocytes. J Neuropathol Exp Neurol; 2005 Feb;64(2):163-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MIB-1 labeling of astrocytes was monitored in a variety of conditions containing significant numbers of reactive astrocytes, including infections, arteriovenous malformations, demyelinating lesions, metastatic tumors, and long-standing gliosis.
  • Astrocytic labeling indices were notably elevated in these cases, with an average labeling index of 5.8%.
  • We conclude that low, but appreciable, astrocytic proliferation may occur in nonneoplastic human astrocytes.
  • These findings have implications for astrocyte function in the normal and disease states and for the diagnostic distinction between reactive lesions and low-grade astrocytic neoplasms.
  • [MeSH-major] Astrocytes / physiology. Brain / cytology. Brain / physiology
  • [MeSH-minor] Adult. Brain Diseases / physiopathology. Cell Proliferation. Child. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751231.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


94. Cui XL, Zhao ZG, Ren XH, Sui DL, Chu JS, Tang K, Zeng C, Lin S: [Characteristics of combining loss of heterozygosity of 1p/19q in glioma]. Zhonghua Wai Ke Za Zhi; 2010 Jun 1;48(11):852-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The status of 1p and 19q of 138 glioma specimen from January 2009 to December 2009 was evaluated by Fluorescence in situ hybridization (FISH) method, and the frequencies of combining LOH of 1p/19q were compared between different pathologies, brain sub-regions, genders and ages.
  • RESULTS: The frequencies of combined LOH of 1p and 19q of oligodendroglial (81.3%) and oligo astrocytic tumors (55.8%) were significantly higher than that of astrocytic tumor (22.2%) (P < 0.01), and the frequency of oligodendroglial tumor was significantly higher than that of oligo astrocytic tumor (P < 0.05).
  • CONCLUSION: Combining LOH of 1p and 19q has significant correlation with the pathologies and brain sub-regions.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21163056.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


95. Kashimura H, Inoue T, Beppu T, Ogasawara K, Ogawa A: Diffusion tensor imaging for differentiation of recurrent brain tumor and radiation necrosis after radiotherapy--three case reports. Clin Neurol Neurosurg; 2007 Jan;109(1):106-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion tensor imaging for differentiation of recurrent brain tumor and radiation necrosis after radiotherapy--three case reports.
  • Fractional anisotropy (FA) is influenced by histological data such as cellularity, vascularity and/or fiber structure in astrocytic tumors.
  • We describe two patients with tumor recurrence and one patient with radiation necrosis who were diagnosed using assessment of FA value.
  • The assessment of FA value in enhanced lesions after radiotherapy may be able to differentiate radiation necrosis from tumor recurrence.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology. Radiation Injuries / pathology
  • [MeSH-minor] Adult. Aged. Anisotropy. Female. Humans. Middle Aged. Necrosis. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793199.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


96. Sadetzki S, Zach L, Chetrit A, Nass D, Hoffmann C, Ram Z, Zaaroor M, Umansky F, Rappaport ZH, Cohen A, Wald U, Rothman S, Hadani M: Epidemiology of gliomas in Israel: a nationwide study. Neuroepidemiology; 2008;31(4):264-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glial brain tumors span a wide range of neoplasms with distinct clinical and histopathological features.
  • This report presents the descriptive epidemiology of glial tumors by histological subtype and tumor behavior.
  • METHODS: The study population included all incident cases of glial tumors diagnosed in Israel during March 2001 to July 2003.
  • RESULTS: A total of 548 tumors were diagnosed, of which 520 had histological confirmation.
  • The ASR of all adult (>20 years) glial tumors was 5.82/100,000 (7.11 for males; 4.75 for females, p < 0.001).
  • The majority of tumors (78%) were classified as high grade; astrocytic tumors were the most frequent (85%), with glioblastoma multiforme accounting for 70% of them.
  • CONCLUSIONS: In general, these results describing data of incident cases of pathologically validated glial tumors are consistent with previous reports.
  • To enhance our understanding of these diseases, epidemiological studies should rely on well-defined histological tumor types, incorporating comprehensive information which will allow comparability between different groups of patients.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioma / epidemiology. Jews / statistics & numerical data
  • [MeSH-minor] Adult. Africa / epidemiology. Aged. Aged, 80 and over. Americas / epidemiology. Asia / epidemiology. Ethnic Groups / statistics & numerical data. Europe / epidemiology. Female. Global Health. Humans. Incidence. Israel / epidemiology. Magnetic Resonance Imaging. Male. Middle Aged. Prevalence. Sex Characteristics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • [CommentIn] Neuroepidemiology. 2008;31(4):270 [18931524.001]
  • (PMID = 18931523.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


97. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T: Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol; 2010 Feb;12(2):173-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades.
  • We evaluated whether cell-free circulating DNA can be used as a noninvasive approach for detection of genetic/epigenetic alterations in brain tumors during the course of the disease.
  • Paired tumor-serum samples from 70 patients with either high-grade astrocytomas (n = 41) or oligodendrogliomas of various grades were analyzed.
  • DNA was extracted from whole blood, serum, and paraffin-embedded tumor sections.
  • LOH and/or methylation that could identify DNA as tumor-specific was found in 80.5% of astrocytic tumors and in all oligodendrogliomas.
  • Statistically significant tumor-serum concordance was found for MGMT methylation in both astrocytic tumors (83%; P < .001) and oligodendroglial tumors (72%; P < .003) and for LOH of 10q (79%; P < .002) and 1p (62%; P < .03) in oligodendrogliomas.
  • We conclude that serum DNA in glial tumors is informative for both LOH and aberrant gene promoter methylation analysis during the course of the disease.
  • The sensitivity is moderate and specificity is high for both low- and high-grade tumors.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. DNA / blood. Glioma / genetics
  • [MeSH-minor] Adult. Aged. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Epigenesis, Genetic. Female. Humans. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. PTEN Phosphohydrolase / genetics. Polymerase Chain Reaction. Sensitivity and Specificity. Tumor Suppressor Proteins / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Brain Pathol. 2009 Apr;19(2):279-92 [18616639.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 [11433041.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):371-5 [11809682.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1461-8 [12684420.001]
  • [Cites] Clin Chem. 2003 Jun;49(6 Pt 1):1028-9 [12766024.001]
  • [Cites] Rocz Akad Med Bialymst. 2003;48:34-41 [14737938.001]
  • [Cites] Pharm Res. 2004 Jul;21(7):1223-8 [15290863.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Pancreas. 1998 Jul;17(1):89-97 [9667526.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):67-70 [9892187.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1219-25 [15709192.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):1-12 [15949585.001]
  • [Cites] Immunol Lett. 2005 Oct 15;101(1):32-40 [15979158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16368-73 [16258065.001]
  • [Cites] Cancer Invest. 2006 Feb;24(1):35-40 [16466990.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1492-5 [16641902.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4270-6 [16963729.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:299-307 [17108224.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:328-33 [17108228.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):583-93 [16909125.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):242-51 [17284109.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):681-5 [17311021.001]
  • [Cites] Pathology. 2007 Apr;39(2):197-207 [17454749.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4545-9 [17510378.001]
  • [Cites] Bioessays. 2007 Jul;29(7):654-67 [17563084.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):548-52 [18385728.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jun;66(3):262-72 [18272388.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):332-7 [18556773.001]
  • [Cites] BJU Int. 2008 Jul;102(2):253-8 [18336598.001]
  • [Cites] Clin Chem. 2008 Sep;54(9):1528-36 [18653827.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Clin Chem. 2009 Mar;55(3):559-67 [19131636.001]
  • [Cites] Lung Cancer. 2009 Apr;64(1):92-7 [18804892.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • (PMID = 20150384.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Proteins; 9007-49-2 / DNA; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2940579
  •  go-up   go-down


98. Maiti AK, Ghosh K, Chatterjee U, Chakrobarti S, Chatterjee S, Basu S: Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytomas. Neurol India; 2008 Oct-Dec;56(4):456-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The involvement of various growth factors, growth factor receptors and proliferative markers in the molecular pathogenesis of astrocytic neoplasms are being studied extensively.
  • Since EGFR and proliferating cell nuclear antigen (PCNA) are involved in mitogenic signal transduction and cellular proliferation pathway, we have studied the correlation between the expression of EGFR and PCNA labeling index in astrocytic tumors.
  • MATERIALS AND METHODS: We investigated the immunohistochemical expression of EGFR and PCNA using the appropriate monoclonal antibodies in 40 cases of astrocytic tumors of which 21 cases were glioblastoma, eight cases were Grade III or anaplastic astrocytomas and six cases were Grade II or diffuse astrocytomas and five cases were Grade I or pilocytic astrocytomas.
  • These suggest that the tumor proliferation, at least in higher grades of astrocytomas is dependent in some measure on EGF and EGFR-related signaling pathways.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19127042.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


99. Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA: Prognostic factors for anaplastic astrocytomas. J Neurooncol; 2007 Feb;81(3):295-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive data on predictive and prognostic factors are lacking for these neoplasms that are considered the most enigmatic entity among the whole spectrum of astrocytic tumors because of their unclear biologic behavior and variable clinical outcome.
  • Potential prognostic biomarkers concern tumor suppressor genes on chromosome 9q that are involved in the RB1 pathway; PTEN, the PI3k/Akt/p70s6k cascade, survivin gene, Formylpeptide receptor, minichromosome maintenance protein 3 and genes on chromosome 7.
  • The state of the art pictured here underlie the recent interest on gene expression profile to identify aberrations useful to understand the biologic behavior of astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / genetics. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Gene Expression Profiling. Humans. Karnofsky Performance Status. Middle Aged. Prognosis


100. Daumas-Duport C, Koziak M, Miquel C, Nataf F, Jouvet A, Varlet P: [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):247-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Definition of homogeneous tumor groups of oligodendrogliomas or oligo-astrocytomas is a basic condition for an adequate evaluation and comparison of the results of treatments in patients from various institutions.
  • However, increasing discordances are observed in the histological diagnosis of these tumors.
  • PATIENTS AND METHODS: This study included 251 adult patients in whom a SA grade A or B oligodendroglioma or oligo-astrocytoma was newly diagnosed at our institution from 1984 to 2003.
  • Routine histological preparations and post-contrast preoperative MRI/CT-scan were simultaneously reviewed in order to assess the impact on survival of the following features: presence or absence of a polymorphous or gemistocytic astrocytic component, of necrosis and of contrast enhancement (CH); endothelial hyperplasia (EH) assessed as absent, present minor (HE+) or (HE++) when conform to the threshold of HE defined in the SA grading system of oligodendrogliomas.
  • The tumors were graded A: no CH and no EH; in B: CH and /or HE++, and A/B: EH + but no CE.
  • RESULTS: 70.1% of the tumors were classified as "pure" oligodendroglioma, 19.5% as "polymorphous oligo-astroastrocytoma" and 10.3% as "gemistocytic oligo-astrocytoma".
  • In grade A, or B tumors, the presence of a polymorphous or a gemistocytic component had no significant influence on survival; however respectively 53% and 65% of these tumours versus 32% of "pure" oligodendrogliomas were grade B at the time of diagnosis.
  • After regrouping of the histological subtypes and of the tumors with HE+ or absent, the series included 153 oligodendrogliomas grade A and 98 grade B.
  • Survival in patients with grade A versus grade B tumors was respectively 142 versus 52 months (p<0.0001).
  • In grade B tumors, necrosis had no significant influence on survival.
  • In tumors with or without CE, patient survival was respectively 148 versus 40 months (p<0.0001).
  • On post contrast MRI done in 235 patients, only 7 tumors (3%) were grade A/B (EH++ but no CH).
  • 1) tumors diagnosed according to the Ste-Anne classification as oligodendroglioma or oligo-astrocytoma be regrouped in a unique category, 2) independent of their histological type and grade according to the WHO, gliomas that do not show CE be regrouped with SA oligodendrogliomas grade A, 3) concerning gliomas that show CE on MRI: oligodendrogliomas or oligo-astrocytomas WHO grade II or III, as well as WHO secondary glioblastomas or glioblastomas with an oligodendroglial component, be regrouped with SA oligodendrogliomas grade B; however tumors that show ring-like CE surrounding large foci of necrosis and finger-like "peritumoral" edema should be excluded or analysed separately.
  • [MeSH-major] Brain / pathology. Brain / radiography. Brain Neoplasms / classification. Glioma / classification. Oligodendroglioma / classification
  • [MeSH-minor] Adult. France. Hospitals. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292168.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement